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THE PATENTABILITY OF GENETIC THERAPIES:
CAR-T AND MEDICAL TREATMENT EXCLUSIONS AROUND THE WORLD

LUIS GIL ABINADER* AND JORGE L. CONTRERAS 1**
Draft: May 15, 2019

ABSTRACT
More than eighty countries, including the members of the European Patent Convention,
the United States, Canada, New Zealand, China, Japan, and India, currently exclude or limit the
patentability of methods of medical treatment. CAR-T and other recent gene and cell therapies,
which operate based on the extraction of genetic or cellular material from a patient, the alteration
of such material, and the reintroduction of such material to the patient’s body, should, under most
or all of these legal regimes, be considered medical treatments that are thus excluded from
patentability, or as to which patent enforcement is limited. Accordingly, we urge national patent
offices to update their examination procedures and practices to take these patentability limitations
into account, and to publish guidance clearly explaining this approach to applicants.
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INTRODUCTION
Recent scientific breakthroughs have enabled the development of a new class of human
therapies that harness a patient’s own cells to achieve therapeutic results. One of the most
promising of these is an immunotherapy that utilizes chimeric antigen receptor T-cells (CAR-T)
to enhance a patient’s ability to combat tumor cells. 2 Other promising types of gene therapy can
replace a defective copy of a patient’s gene with a modified gene that is inserted into the patient’s
cells.3 Researchers continue to explore stem cell treatments that will make use of regenerative
pluripotent stem cells harvested from a patient’s body.
While treatments such as these have been discussed for years, it is only recently that
regulatory agencies have begun to approve them for use in human patients. In 2017, the U.S. Food
and Drug Administration (FDA) approved the first two CAR-T therapies for use in the United
States: Novartis’s Kymriah (tisagenlecleucel)4 and Kite/Gilead’s Yescarta (axicabtagene
ciloleucel),5 both of which are indicated for blood-based cancers (lymphoblastic leukemia and Bcell lymphoma, respectively). European and Canadian approval of these treatments followed in
2018.6
While these new therapies have the potential to save and drastically improve human life,
their announced prices have also set new records. Kymriah reportedly costs US$475,000 per
treatment,7 and Yescarta will be priced at US$373,000.8 And recently Novartis announced that $4–
5 million per patient would be a “cost effective” price for a gene therapy under development for
spinal muscular atrophy (SMA). 9 These high price tags portend a large and highly lucrative market
ahead for CAR-T and similar therapies. One market analyst predicts that the global CAR-T market
will expand from $168 million in 2018 to $8 billion in 2028. 10
Given the high profits anticipated from these novel therapies, it is not surprising that the
firms developing them have sought patents covering many aspects of their manufacture,
composition, and use. 11 However, unlike new small molecule drugs and biologics, these therapies
are not novel compounds or biological entities but modified versions of a patient’s own cells. 12 As
2

See, e.g., Denise Grady, F.D.A. Approves First Gene-Altering Leukemia Treatment, Costing $475,000, N.Y. Times
(Aug. 30, 2017), https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html (describing the University of
Pennsylvania researchers’ treatment using the CAR-T cell therapy).
3
Gina Kolata, New Gene-Therapy Treatments Will Carry Whopping Price Tags, N.Y. Times (Sept. 11, 2017),
https://www.nytimes.com/2017/09/11/health/cost-gene-therapy-drugs.html.
4
See U.S. Food & Drug Ass’n, BL 125646/0, Biologics License Application Approval Letter for Novartis
Pharmaceuticals 1 (Aug. 30, 2017) [hereinafter Novartis Approval Letter].
5
See U.S. Food & Drug Ass’n, BL 125643/0, Biologics License Application Approval Letter for Kite Pharma 1
(Oct. 18, 2017) [hereinafter Kite Approval Letter].
6
See discussion infra Section I.B.3 (discussing regulatory approvals).
7
Kolata, supra note 2.
8
Deena Beasley, U.S. Medicare Sets Outpatient Rate for Yescarta Reimbursement, Reuters (Apr. 5, 2018),
https://www.reuters.com/article/us-cancer-medicare-yescarta/u-s-medicare-sets-outpatient-rate-for-yescartareimbursement-idUSKCN1HC2N3.
9
John Miller, Novartis Says SMA Gene Therapy is Cost-Effective At $4-5 Mln Per Patient, Reuters (Nov. 5, 2018),
https://www.reuters.com/article/novartis-gene-therapy/novartis-says-sma-gene-therapy-is-cost-effective-at-4-5-mlnper-patient-idUSFWN1XG0OD.
10
Jeannie Baumann, Breakthrough Cancer Therapy Stalls in Manufacturing Bottleneck, Bloomberg Law News, Feb.
12, 2019.
11
See discussion infra Section II (discussing patent coverage).
12
See Grady, supra note 1 (stating that these treatments “turn patient’s cells into a ‘living drug’”).
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such, one must ask whether therapies such as Kymriah and Yescarta are drugs, as their
manufacturers characterize them, or methods of medical treatment. The distinction is a crucial one,
as the laws of more than eighty countries around the world prohibit the patenting of methods of
medical treatment, and even countries such as the United States, Canada, and Australia, which do
not expressly prohibit such patents, may significantly limit the scope of patenting and enforcement.
13

In this article we ask whether therapies that act primarily to alter a patient’s own cells,
particularly CAR-T therapies such as Kymriah and Yescarta, should be considered methods of
medical treatment that are largely ineligible for patent protection around the world and, if so, how
national patent offices, legislatures, and courts should respond. 14 The remainder of this article
proceeds in four principal Parts as follows: Part I provides an overview of the scientific and
regulatory background of CAR-T and other gene and cell therapies such as Kymriah and Yescarta.
Part II describes the patenting exclusion for methods of medical treatment around the world. Part
III analyzes the degree to which CAR-T and other gene and cell therapies should be considered
methods of medical treatment that are ineligible for patent protection, or subject to limitations on
patent protection. And Part IV considers the implications of the potential loss of patentability on
the development and market for such therapies, as well as potential governmental reactions.
I. CAR-T AND GENETIC THERAPIES
While a number of different therapy types make use of a patient’s cells, we focus in this
article on CAR-T therapies, both because they present a clear case for characterization as
therapeutic methods and because there are multiple CAR-T therapies that have received regulatory
approval and are now being administered to human patients.15
A. Overview of CAR-T Therapy
Broadly speaking, CAR-T therapies involve the modification of a patient’s T-lymphocytes
(white blood cells that play a key role in the immune system) so as to target particular forms of
tumor cells.16 An overview of the CAR-T treatment process is illustrated in Fig. 1 (note its
characterization as a “cell manufacturing” process by the vendor).

13

See Paul Mazzola, Primer on Patenting Methods of Medical Treatment in the United States and Abroad, Healio
(Aug. 4, 2017), https://www.healio.com/orthopedics/business-of-orthopedics/news/online/%7B9b2e4d7f-e2b1-4be9a728-7bccf1dc0a3b%7D/primer-on-patenting-methods-of-medical-treatment-in-the-united-states-and-abroad
(highlighting Australia, Canada, and Europe’s patentability limitations on methods of human therapy treatments).
14
But see Jacob S. Sherkow, Patricia J. Zettler, and Henry T. Greely, Is It 'Gene Therapy'?, J.L. Biosci. (2018) (“all
therapies, in some sense, affect a patient’s genes, whether it’s through altering transcription, regulating translation, or
even modifying the epigenome. A relaxing vacation—sun, surf, and sangria—arguably does more to regulate gene
expression than many ‘precision’ therapies").
15
See, e.g., NCI Staff, With Federal Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the
Clinic, Nat’l Cancer Inst. (Oct. 25, 2017), https://www.cancer.gov/news-events/cancer-currents-blog/2017/yescartafda-lymphoma (stating that the Food and Drug Administration approved the use of “axicabtagene ciloleucel
(Yescarta™)” in treating patients with large-B-cell lymphomas).
16
See id.
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Figure 1 – Overview of CAR-T cell manufacturing process17
As shown in Figure 1, the first stage of CAR-T treatment is the extraction of T-cells from
a patient’s body through a procedure known as leukapheresis. 18 While leukapheresis is performed
on site at the patient’s healthcare facility, extracted cells are sent to a centralized laboratory (in the
case of Kymriah, a Novartis’s facility in either Morris Plains, New Jersey or Fraunhofer,
Germany).19 Because leukapheresis collects multiple cell types in a mixture that may vary based
on the patient’s disease stage, genetics, age, and treatment history, the collected cellular material
must be processed to reduce these impurities.20 If insufficient T-cells remain, T-cell enrichment
steps may be necessary. 21
Once the patient’s T-cells are collected and processed, they are treated with synthetic
antigen receptors (CARs) that are known to bind to particular proteins expressed on the surface of
tumor cells.22 In the case of Kymriah, the target protein is known as CD19, which is expressed on
the surface of B cell tumors.23 A retroviral vector then introduces the synthetic CAR to the patient’s
T-cells.24 In some cases, the vector may be inserted into the T-cell using a gene editing technique

U.S. Food & Drug Ass’n, BLA 125646, FDA Briefing Document for Tisagenlecleucel, Novartis
Pharmaceuticals 14 (2017) [hereinafter Novartis FDA Briefing].
18
Id. at 18.
19
See id. at 43.
20
See id. at 18.
21
Id.
22
Id. at 14. See generally Carl H. June & Michael Sadelain, Chimeric Antigen Receptor Therapy, 379 N. Eng. J.
Med. 64 (2018) (providing an overview of the technology).
23
Id. at 16.
24
See id. at 17; see also Justin Eyquem et al., Targeting a CAR to the TRAC Locus with CRISPR/Cas9 Enhances
Tumour Rejection, 543 Nature 113, 113 (2017).
17

Electronic copy available at: https://ssrn.com/abstract=3391788

6

Abinader and Contreras

CAR-T

such as CRISPR-Cas9.25 The modified T-cells, which the manufacturer refers to as its “product,”
are then reintroduced to the patient’s bloodstream at the healthcare facility. 26
In the patient’s body, the modified T-cells are attracted to tumor cells by means of their
new antigen receptors. 27 Once a modified T-cell comes into proximity with a tumor cell, it attacks
the tumor by releasing toxic granules (cytotoxicity) or by signaling other cells to attack the tumor
(cytokine signaling). 28 These mechanisms are illustrated in Fig. 2 and have proven to be clinically
efficacious.29 Novartis reported a complete remission rate of 82.5% six months after Kymriah was
administered in a Phase II single-arm multicenter trial in pediatric patients with relapsed or
refractory B-cell acute lymphoblastic leukemia. 30

Figure 2 – Tisagenlecleucel mechanisms of action 31

25

Eyquem et al., supra note 22, at 113.
Novartis FDA Briefing, supra note 17, at 1, 8, 9.
27
Id. at 17.
28
Id. at 17–18.
29
Id. at 15.
30
Id. at 8.
31
Novartis FDA Briefing, supra note 17, at 15.
26
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B. Regulatory Approval of Gene and Cell Therapies
1. U.S. Regulatory Framework for Gene Therapies
In the United States, gene and cell therapies are regulated as biological products, or
biologics, under the Public Health Service Act (PHSA)32 and the Federal Food, Drug, and
Cosmetic Act (FDCA). 33 An applicant seeking approval to market and distribute a new biologic in
the United States must complete preclinical laboratory tests, animal studies, and formulation
studies as well as human clinical trials to establish the safety, potency, and purity of the product
candidate for each proposed indication. 34
In addition, the FDA defines a “gene therapy product” as a product that operates by
transcription and/or translation of transferred genetic material and/or by integrating into the host
genome, and which is administered using nucleic acids, viruses, or genetically engineered
microorganisms.35 Gene therapy products may be used to modify cells in vivo or transferred to
cells ex vivo prior to administration to the recipient. 36 The FDA and the NIH have published
guidance documents with respect to the development and submission of protocols for gene therapy
products that provide additional factors that the FDA will consider at each stage of development. 37
In order to obtain marketing approval for a new gene therapy product, an applicant must
submit a Biologics License Application (BLA) to the FDA requesting marketing approval for one
or more proposed indications, including detailed information on the manufacture and composition
of the product and its proposed labeling. 38 The BLA must contain extensive manufacturing
information and detailed information on the composition of the product and its proposed labeling. 39
As part of its BLA review, the FDA will inspect the manufacturing facilities at which the
proposed product and its components will be produced to assess compliance with the FDA’s
current Good Manufacturing Practices (cGMP) requirements and to assure that the facilities,
methods, and controls are adequate to preserve the product’s identity, strength, quality, and
purity.40 In addition, when human cellular and tissue products are involved, the FDA will assess
the applicant’s compliance with the FDA’s Current Good Tissue Practices (CGTP), which seek to

32

See Public Health Service Act, 42 U.S.C. § 262 (2017) (establishing the procedures for the issuance of biologics
licenses).
33
See Federal Food, Drug, & Cosmetic Act, 21 U.S.C. § 301 (2017) (authorizing the FDA to generally oversee the
safety of food, drugs, medical devices, and cosmetics in the United States).
34
U.S. Food & Drug Ass’n, Chemistry, Manufacturing, and Control (CMC) Information for Human Gene
Therapy Investigational New Drug Applications (INDs) 1–2 (2018) [hereinafter INDs Information] (“This
guidance applies to human gene therapy products and to combination products that contain a human gene therapy in
combination with a drug or device.”).
35
U.S. Food & Drug Ass’n, Guidance for Industry: Gene Therapy Clinical Trials – Observing Subjects for
Delayed Adverse Events 4 (2006) [hereinafter FDA Gene Therapy Guidance] (defining gene therapy products as
“[a]ll products that mediate their effects by transcription and/or translation of transferred genetic material and/or by
integrating into the host genome and that are administered as nucleic acids, viruses, or genetically engineered
microorganisms”). See generally Sherkow et al, supra note 16 (overview of FDA’s attempts to define “gene therapy”).
36
Id.
37
See id. at 8.
38
21 C.F.R. § 601.2(a) (2018).
39
Id.
40
Id. § 606.40.
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ensure that cell and tissue based products are manufactured in a manner designed to prevent the
introduction, transmission, and spread of communicable disease. 41
The FDA may approve a BLA if it determines that the proposed biologic product is safe,
pure, and potent and the facility where the product will be manufactured meets all required
standards.42 Upon approval of a BLA, the FDA may issue an approval letter or a complete response
letter.43 An approval letter authorizes commercial marketing of the product with specific
prescribing information for specific indications. 44 If the application is not approved, the FDA will
issue a complete response letter, which will contain the conditions that must be met in order to
secure final approval of the application, and when possible will outline recommended actions the
sponsor might take to obtain approval of the application. 45
2. EU Regulatory Framework for Gene Therapies
The process governing approval of medicinal products in the European Union is similar to
that in the United States. It entails satisfactory completion of preclinical studies and adequate and
well-controlled clinical trials to establish the safety and efficacy of the product for each proposed
indication.46 In order to receive marketing approval for a new product in the EU, an applicant must
submit a marketing authorization application (MAA) under a centralized procedure administered
by the European Medicines Agency (EMA). 47
The marketing of products containing viable human tissues or cells such as gene therapy
medicinal products is governed by Regulation (EC) No 1394/2007 on advanced therapy medicinal
products, read in combination with Directive 2001/83/EC of the European Parliament and of the
Council, commonly known as the Community code on medicinal products. 48 Regulation (EC) No
1394/2007 establishes specific rules concerning the authorization, supervision, and
pharmacovigilance of “gene therapy medicinal products”, “somatic cell therapy medicinal
products”, and “tissue engineered products”.49 Manufacturers of such advanced therapy
“medicinal products” must demonstrate their quality, safety, and efficacy to EMA, which renders
an opinion regarding the application for marketing authorization. 50 The European Commission
then grants or refuses marketing authorization in light of the opinion delivered by EMA. 51 We note
however that the characterization of gene and cell therapies as a “product”, as the in the Directive
2001/83/EC which uses phrases such as “somatic cell therapy medicinal products”, is largely a
fiction. Here the “product” in question is a batch of the patient’s own cells that are taken from the
U.S. Food & Drug Ass’n, Guidance for Industry: Current Good Tissue Practice (CGTP) and Additional
Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
3 (2011) [hereinafter FDA Good Tissue Practice Guidance].
42
§ 610.9(a)-(b) (outlining the requirements for the modification of a test method or manufacturing process).
43
21 C.F.R. § 601.3(a) (2018).
44
Drugs@FDA
Glossary,
U.S.
Food
&
Drug
Admin.,
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=glossary.page (last accessed Mar. 30, 2019).
45
§ 601.3(a)(2).
46
Council Regulation 2017/745, 2017 O.J. (L 117) 1, 1–2 (EU).
47
Id. at 2, 13 (“[T]he Commission should ensure an appropriate level of consultation of the European Medicines
Agency (EMA), the European Chemicals Agency and the European Food Safety Authority.”).
48
Council Regulation 1394/2007, 2007 O.J. (L 324) 121 (EC); Council Directive 2001/83/EC, 2001 O.J. (L 311) 67
(EC).
49
Council Regulation 1394/2007, supra note 45, at 121.
50
Id. at 122, 124.
51
Id.
41
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patient, altered, and then re-introduced into the patient’s body. We discuss this further in Part III.B,
below.
3. Recent CAR-T Regulatory Approvals
The first applicant to seek U.S. regulatory marketing approval for a CAR-T candidate
therapy appears to have been Juno Therapeutics, a leader in CAR-T research.52 Juno’s JCAR015
therapy was jointly developed with Cellgene and targeted Adult B-cell acute lymphoblastic
leukemia (ALL).53 But despite early promise, the FDA halted Juno’s JCAR015 Phase II trial in
March 2017 after five patient deaths resulting from cerebral edema. 54 Juno is reportedly in clinical
trials for one or more additional CAR-T based therapies.55
Novartis received U.S. market approval for Kymriah (tisagenlecleucel) on August 30,
2017. This approval authorizes Kymriah as “a CD19-directed genetically modified autologous T
cell immunotherapy indicated for the treatment of patients up to 25 years of age with B-cell
precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.” 57
Because of the pediatric indication for which Kymriah was approved, Novartis also received a
transferable, salable “rare pediatric disease priority review voucher” under Section 529 of the
Food, Drug, & Cosmetic Act. 58 Because the indication for which Kymriah’s market approval was
sought affects fewer than 200,000 individuals in the U.S., Novartis was also granted “orphan drug”
status for Kymriah. 59
56

Novartis received market approval for Kymriah in the EU on August 27, 2018. 60 This
approval authorizes the marketing of Kymriah in the EU for two indications: the treatment of B
cell ALL that is refractory, in relapse post-transplant or in second or later relapse in patients up to
25 years of age; and the treatment of relapsed or refractory diffuse large B cell lymphoma

52

Alex Lash, After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy, Xconomy (Mar. 1, 2017),
https://xconomy.com/seattle/2017/03/01/after-trial-deaths-juno-pivots-and-scraps-lead-car-t-therapy/.
53
Id.
54
Id.
55
Id.
56
Novartis Approval Letter, supra note 3, at 1.
57
Id.
58
Id. at 4.
59
Novartis Approval Letter, supra note 3, at 5. Orphan drug designation in the United States is designed to encourage
sponsors to develop products intended for rare diseases or conditions (i.e., conditions that affect fewer than 200,000
individuals in the United States or that affect more than 200,000 individuals in the United States and for which there
is no reasonable expectation that the cost of developing and making available the product will be recovered from U.S.
sales of the product). An orphan drug designation granted by the FDA confers on the sponsor a seven-year market
exclusivity. An application for designation as an orphan product can be made any time prior to the filing of an
application for approval to market a product. See Developing Orphan Products: FDA and Rare Disease Day, FDA
(2011), https://www.fda.gov/forindustry/Developingproductsforrarediseasesconditions/ucm239698.htm.
60
Summary of European Union Decisions on Marketing Authorization in Respect of Medicinal Products from 1
August 2018 to 31 August 2018, 2018 O.J. (C 349) 1, 2 (EC).
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(DLBCL) after two or more lines of systemic therapy in adult patients. 61 Kymriah also received
orphan market exclusivity in Europe.62
Novartis obtained approval for Kymriah in Canada on September 5, 2018. 63 The
authorization by Health Canada covers the following indication: treatment of pediatric and young
adult patients 3 to 25 years with B-cell ALL who are refractory, have relapsed after allogeneic
stem cell transplant (SCT) or are otherwise ineligible for SCT, or have experienced second or later
relapse.64
Kite Pharma received U.S. market approval history for Yescarta (axicabtagene ciloleucel)
on October 18, 2017.65 This approval authorizes Yescarta “for the treatment of adult patients with
relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including
diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell
lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.” 66
Kite Pharma received market approval for Yescarta in the EU on August 27, 2018. 67 This
approval grants Yescarta an orphan market exclusivity that is due to expire on August 27, 2028.68
In the EU Yescarta is indicated for the treatment of adult patients with relapsed or refractory diffuse
large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after
two or more lines of systemic therapy. 69
Most recently, CRISPR Therapeutics has received FDA approval for an investigational
new drug application for its CTX001 CAR-T therapy targeting beta thalassemia and sickle cell
disease.70

See
Product
Information
(Kymriah),
Eur.
Comm’n:
Public
Health,
http://ec.europa.eu/health/documents/community-register/html/h1297.htm. (last visited Feb. 18, 2019) (explaining the
parameters for authorized marketing of Kymriah).
62
See id. EC Regulations No. 141/2000 and No. 847/2000 provide that a product can be designated as an orphan drug
by the European Commission if its sponsor can establish that the product is intended for the diagnosis, prevention, or
treatment of (i) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand
persons in the EU, or (ii) a life-threatening, seriously debilitating, or serious and chronic condition in the EU that,
without additional incentives, is unlikely to generate sufficient returns to justify the investment necessary to produce
and market the product. In each of these cases, the applicant must demonstrate that no authorized method of diagnosis,
prevention, or treatment of the condition in question exists or, if such method exists, the product will be of significant
benefit to those affected by the relevant condition. Marketing authorization for an orphan drug confers a ten-year
period of market exclusivity (which may be reduced to six years if, at the end of the fifth year, the product no longer
meets the criteria for orphan drug designation). See Council Regulation 141/2000, 2000 O.J. (L 18) 1, 4–5 (EC);
Commission Regulation 847/2000, 2000 O.J. (L 103) 1, 5 (EC).
63
Regulatory Decision Summary – Kymriah – Health Canada, Gov. Can.: Health Product Reg., https://hprrps.hres.ca/reg-content/regulatory-decision-summary-detail.php?linkID=RDS00423 (last visited Feb. 18, 2019).
64
Regulatory Decision Summary – Kymriah – Health Canada, supra note 60.
65
See Kite Approval Letter, supra note 4.
66
Id.
67
Summary of European Union Decisions on Marketing Authorization in Respect of Medicinal Products from 1
August 2018 to 31 August 2018, supra note 57, at 2.
68
Product Information (Yescarta), Eur. Comm’n: Pub. Health, http://ec.europa.eu/health/documents/communityregister/html/h1299.htm#EndOfPage (last visited Feb. 18, 2019).
69
Id.
70
Bailey Lipschultz, Crispr Got FDA Nod for Another Gene Editing Study, Dosing Next, Bloomberg Law News, Apr.
29, 2019.
61
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Beyond this, many more CAR-T and other gene and cell therapy are likely to seek
regulatory approval in the near future. One commentator reports that in February 2019, there were
nearly 700 CAR-T studies registered in the NIH’s ClinicalTrials.gov database. 71
C. The Patenting of CAR-T
As with many new biomedical developments, the firms bringing CAR-T treatments to
market have acquired patents covering many aspects of these treatments. One of the first U.S.
patents covering CAR-T technology is entitled “Nucleic Acids Encoding Chimeric T Cell
Receptors” and was issued in 2008 to the Sloan-Kettering Institute for Cancer Research in New
York.72 The thirteen claims of this patent (one independent and twelve dependent) claim various
configurations of a “nucleic acid polymer encoding a chimeric T cell receptor”—a composition of
matter.73 This patent, in turn, has been cited by ninety-seven later patents and patent applications. 74
As discussed below, many of these later patents and applications claim not only compositions of
matter, but methods of treating various diseases using CAR-T technologies.75
In April 2019, Björn Jürgens and Nigel Clarke published a study of CAR-T patenting
commissioned by the European Patent Office (EPO). 76 Jürgens and Clarke report that the patenting
of CAR-T inventions began in earnest in 2013 with sixty filings around the world and increased
through 2016 to 597 filings. 77 Of a total of 1,914 patent documents filed between 2013 and 2016,
the greatest number were filed by applicants originating in the U.S. (39%) and China (33%),
followed by the UK (5%), Germany (5%), Japan (4%) and France (3%). 78 The jurisdictions in
which patent documents were filed included the U.S. (approximately 380 documents), the EPC
(approximately 190 documents), Australia (approximately 160 documents) and Canada
(approximately 130 documents).79
The authors conducted a further analysis of CAR-T patent filings. Table 1 shows the results
of a search in the USPTO patent database for issued patents and published patent applications
containing the term “chimeric antigen receptor” either in all of the search fields, in their abstracts,
or in their claims. 80

71

Baumann, supra note 12.
See U.S. Patent No. 7,446,190 B2 (filed May 28, 2003) (issued Nov. 4, 2008) (featuring the full patent for Nucleic
Acids Encoding Chimeric T Cell Receptors).
73
Id. (“This application relates to nucleic acid polymers encoding chimeric T cell receptors. . . .”).
74
See
Nucleic
Acids
Encoding
Chimeric
T
Cell
Receptors,
Google
Patents,
https://patents.google.com/patent/US7446190B2/en?oq=7%2c446%2c190 (search “Pat. No. 7,446,190” then scroll
down to “cited by”) (last visited Feb. 18, 2019) (providing a list of all publications that have cited to Pat. No.
7,446,190).
75
See discussion infra Part X.
76
Björn Jürgens & Nigel Clarke, Evolution of CAR T-cell immunotherapy in terms of patenting activity, 37 Nature
Biotechnology 230 (2019).
77
Id. at 371.
78
Id. at 372.
79
Id.
80
See Chimeric Antigen Receptor, U.S. Pat. and Trademark Off., http://patft.uspto.gov/netahtml/PTO/searchbool.html (search “Chimeric Antigen Receptor” then adjust dates) (last visited Feb. 20, 2019); see also Chimeric
Antigen Receptor, U.S. Pat. and Trademark Off., http://appft.uspto.gov/netahtml/PTO/search-bool.html (search
“Chimeric Antigen Receptor”) (last visited Feb. 20, 2019). This search strategy is consistent with that of Jürgens &
Clarke, supra note 75, at Supp.
72
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Table 1
U.S. issued patents and patent applications citing “chimeric antigen receptor”, by year

Issued patents
Year

All fields

Abstract

81

Published applications
Claims

All fields

Abstract

Claims

2011

0

0

0

6

0

0

2012

0

0

0

12

1

7

2013

4

0

2

32

3

15

2014

10

1

6

65

20

38

2015

27

1

12

104

14

45

2016

64

8

24

239

35

123

2017

117

15

41

455

67

200

2018

195

14

57

730

103

327

Table 1 is not intended to be a comprehensive landscape of CAR T patenting activity in
the U.S.82 Although the fact that a patent document mentions the phrase “chimeric antigen
receptor” in the description or any other field is indicative, this does not necessarily mean that it
is claiming a CAR T therapy. Conversely, CAR T therapies may be claimed in patent documents
without using the phrase “chimeric antigen receptor,” and such patent documents are not included
in the search strategy described in Table 1. For instance, as of March 2019, there are three issued
patents in the U.S. that use the phrase "synthetic T-cells" but do not mention the phrase “chimeric
antigen receptor”; similarly, there is one issued patent in the U.S. citing "CAR-modified T-cells"
that does not mention “chimeric antigen receptor.” Nevertheless, Table 1 provides an easilyreplicable illustration of the growth in patents and applications mentioning “chimeric antigen
receptor.”
In Europe, the number of CAR-T patents appears to be lower. An Espacenet search for B1,
B2, or B3 documents (codes used to identify granted patents) citing the phrase "chimeric antigen
receptor" in the title or abstract only returns nine European patents. 83 Two of those patents claimed
methods where one of the steps involves administering T cells to a patient. 84

81

Id.
For patent landscaping guidelines in the life sciences, see e.g., Tania Bubela, E Richard Gold, Gregory D Graff,
Daniel R Cahoy, Dianne Nicol and David Castle. Patent landscaping for life sciences innovation: toward consistent
and transparent practices. 31 Nature Biotechnology 202 (2013); Mateo Aboy, Kathy Liddell, Johnathon Liddicoat,
and Cristina Crespo. Myriad's Impact on Gene Patents. 34 Nature Biotechnology, 1119 (2016).
83
See Espacenet Patent Search, Eur. Pat. Off., https://worldwide.espacenet.com (last visited Feb. 16, 2019) (listing
all patents within this search, including those from countries outside of Europe).
84
See id.
82
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A PatentScope search85 for applications that include any of the following phrases:
"administering to a patient," "administering to a subject," "administering to said subject," and
"administering to said patient," conducted in October 2018, returned a total of eighty-three patent
applications filed at the EPO. A review of these eighty-three applications using the European
Patent Register online legal status database 86 reflects that as of December 2018, seventy-five of
those applications were still pending,87 and six have been withdrawn. The EPO has expressed its
intent to grant only two of those eighty-three applications; in both of those applications the claims
with the term “administering [...]" were abandoned, eliminated during examination, or were not
introduced at the EPO despite being present in the priority application. 88 These figures are lower
than those reported by Jürgens & Clarke, most likely due to the more restrictive search terms that
we employed.

II. PATENT EXCLUSIONS FOR METHODS OF MEDICAL TREATMENT
A. Background: Nineteenth and Early Twentieth Centuries
Since the early days of patenting there has been unease with regard to granting particular
inventors exclusive rights over methods of medical treatment. Objections to the patenting of
medical treatments have their roots in basic moral principles—it is wrong to limit the availability
of potential lifesaving treatments to individuals in need—as well as ethical precepts of the medical
profession.89 That is, in keeping with the Hippocratic Oath, it was argued that “in order to ensure
the best possible health treatment, physicians must always be free in their choice of treatment.” 90
Thus, when the American Medical Association adopted its first Code of Ethics in 1847, its
members agreed that obtaining a patent on a medical procedure was “derogatory to professional
character.”91

85

See Word Intell. Prop. Org.: Patentscope, https://patentscope.wipo.int/search/en/search.jsf (last visited Feb. 16,
2019) (providing the complete results of the aforementioned search).
86
European Patent Register, Eur. Pat. Off., https://register.epo.org/regviewer (last visited Feb. 16, 2019).
87
Id. In the context of this paper pending means that a published application has not yet been issued, rejected, or
withdrawn. At the European Patent Register database, the legal status of pending applications could be coded in several
ways, including as “the application has been published”, “request for examination was made”, “examination is in
progress.”
88
European Patent Register, supra note 76.
89
O. Mitnovetski & D. Nicol, Are Patents for Methods of Medical Treatment Contrary to the Ordre Public and
Morality or “Generally Inconvenient”?, 30 J. Med. Ethics 470, 470 (2004) (“Medical law has its origins in the
Hippocratic Oath, and the goal is the preservation of human life. Since the goal of patent law is to encourage innovation
by rewarding inventors, it is quite distinct from the goal of medical law.”).
90
Id.
91
See Katherine J. Strandburg, Derogatory to Professional Character? The Evolution of Physician Anti-Patenting
Norms, in Creativity Without Law: Challenging the Assumptions of Intellectual Property 63, 63 (K. Darling &
A. Perzanowski eds., 2017) [hereinafter Strandburg, Derogatory to Professional Character?]; see also Katherine J.
Strandburg, Legal But Unacceptable: Pallin v. Singer and Physician Patenting Norms, in Intellectual Property at the
Edge 321, 323 (Rochelle Dreyfuss & Jane Ginsburg eds., 2014) [hereinafter Strandburg, Legal But Unacceptable]
(specifying that the first Code of Ethics in 1847 found it to be unethical for a physician to hold a patent). In the early
years of the twentieth century, a similar aversion to the patenting of drugs can be found. See Joseph Gabriel, Medical
Monopoly (2014).
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Patent offices and courts around the world generally agreed with the assessment of the
medical community and effectively prohibited patents on methods of medical treatment through
the nineteenth and early twentieth centuries.92 Accordingly, patents were denied or invalidated in
the United States for the use of ether as a surgical anesthetic 93 and for the treatment of skin
infections using light rays. 94 Patents were also denied in the United Kingdom for a process for
extracting toxic lead from a patient, 95 and in Germany for the therapeutic administration of oxygen
through a hydrogen peroxide bath.96 In many of these cases, particularly in Europe, courts reasoned
that a patent could not be issued for a process that failed to result in a “vendible product”—
something that could be sold. 97 France and Italy adopted a test of “industrial character” for the
issuance of patents on medical innovations, 98 and Austria and Switzerland based the refusal of
such patents on ethical grounds. 99
Yet despite these early inclinations against patenting medical treatments, the tide began to
shift during the 1950s. One watershed occurred in 1954, when the U.S. Patent and Trademark
Office expressly overturned an 1883 decision prohibiting the patenting of medical procedures. 100
In 1959 the Australian High Court ruled that a method need not result in a “vendible product” in
order to be patentable, expressly departing from the earlier rule expressed in the UK. 101 These
events, and the increase in patenting activity that followed, contributed to renewed interest in
medical treatment patents around the world.

92

See Strandburg, Legal but Unacceptable, supra note 81, at 321–23 (outlining the early history of the medical
community’s attitude towards medical patents); see also Mitnovetski & Nicol, supra note 79, at 471–72 (tracing the
history in the UK and Europe of excluding medical treatments from patenting).
93
Morton v. New York Eye Infirmary, 17 F. Cas. 879, 884 (C.C.S.D.N.Y. 1862) (No. 9865); see Strandburg,
Derogatory to Professional Character?, supra note 81, at 64–74 (describing the ether patenting controversy).
94
See Ex Parte Brinkerhoff, 24 Dec. Comm’r 349 (1883), reprinted in New Decisions, 27 J. Pat. & Trademark Off.
Soc’y 793, 798 (1945) (discussing a patent on “treating animal tissues by subjecting the same to the action of light
rays lying within a certain region of the spectrum, the tissues being shielded from wave lengths lying within other
regions of the spectrum”).
95
In the Matter of C. & W.’s Application for a Patent, 31 RPC 235, 235–36 (1914).
96
Badewasser Patent, Dec. 30, 1904, Blatt für Patent-, Muster- und Zeichenwesen [BlfPMZ], vol. 11, no. 1, at 4–5
(Jan. 25, 1905) (Ger.), https://babel.hathitrust.org/cgi/pt?id=mdp.35112104213360;view=1up;seq=25.
But see Reiner Moufang, Methods of Medical Treatment Under Patent Law, 24 Intern. Rev. Ind. Prop. & Copyright
L. 18, 22 note 13 (1993) (listing a handful of early German patents issued on medical methods, but never challenged
in court, e.g., German patent No. 150666 (1903) for a method of removing stitches from wounds, and German patent
No. 150699 (1903) for treating human spinal curvature).
97
Mitnovetski & Nicol, supra note 79, at 471 (“[I]t [has been] accepted as axiomatic that there [can] be no patents for
medical treatment, because they do not result in . . . a product that can be sold.”).
98
Id.
99
Id.
100
See Ex parte Scherer, 103 U.S.P.Q (BNA) 107, 110 (Pat. Off. Bd. App. 1954) (stating, in regards to Morton, “[i]t
is believed that no proper inference that any and all medical or surgical methods are excluded from the field of
patentable subject matter can be drawn from the opinion, and neither do the facts upon which the opinion is based
warrant such a broad generalization.”); see also Strandburg, Derogatory to Professional Character? The Evolution of
Physician Anti-Patenting Norms, supra note 81, at 76; William D. Noonan, Patenting Medical and Surgical
Procedures, 77 J. Pat. & Trademark Off. Soc’y 651, 655 (1995) (adding that, in 1948, the American Medical
Association Judicial Council issued an Official Opinion stating that is no longer considered medical patents to be
necessarily unethical).
101
See Nat’l Research Dev. Corp. v. Comm’r of Patents, (1959) 102 CLR 252, 253 (Austl.) (holding that the product
was patentable because “it consist[ed] in an artificially created state of affairs . . .[a]nd the significance of the product
is economic; for it provides a remarkable advantage”); see also Mitnovetski & Nicol, supra note 79, at 471.
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B. The Methods of Treatment Exclusion Under the European Patent Convention
The European Patent Convention (EPC) is a multilateral treaty among thirty-eight
European signatory states representing both members and non-members of the European Union. 102
It establishes a system whereby patent applications may be filed and examined for patentability by
a common agency, the European Patent Office (EPO) based in Munich, and then issued as national
patents in each of the signatory states (subject to translation and other procedural requirements). 103
Negotiations and planning for the EPC began as early as 1949 and, in various fits and starts,
evolved through numerous stages. 104 By 1969, a first draft of the EPC was developed which listed
numerous exclusions from patentability, including “methods of treatments, including methods of
diagnosis.”105
There was debate throughout the negotiation of the EPC whether this exclusion from
patentability was based on the notion that patents on medical treatments were contrary to ordre
public and morality106 or because, as argued by the German delegation, such patents were not
“susceptible of industrial application”107 (i.e., harkening back to the UK’s original assessment of
such patents as failing to result in vendible products). By the signing of the EPC in 1973, the
German view prevailed, and Article 52[4] provided that
Methods for treatment of the human or animal body by surgery or therapy and
diagnostic methods practised on the human or animal body shall not be regarded as
inventions which are susceptible of industrial application . . . This provision shall
not apply to products, in particular substances or compositions, for use in any of
these methods.108

102

Convention on the Grant of European Patents, Oct. 5, 1973, 1065 U.N.T.S. 199 (entered into force Oct. 7, 1977),
as amended by the Act revising the Convention on the Grant of European Patents of Nov. 29, 2000 (entered into force
Dec. 13, 2007) [hereinafter EPC].
103
See id. (explaining the process and requirements for obtaining a patent in Europe).
104
See Sigrid Sterckx & Julian Cockbain, Exclusions from Patentability: How Far Has the European Patent
Office Eroded Boundaries? 21–39 (Cambridge Univ. Press ed. 2012) (outlining the historical development of the
EPC).
105
EPC, First Preliminary Draft of a Convention Establishing a European System for the Grant of Patents, art. 9(2)(e)
(1970) [hereinafter EPC, First Preliminary Draft of a Convention Establishing a European System for the Grant of
Patents]. The debates over the EPC were extensive and lengthy. In terms of exclusions from patentability, topics such
as the patentability of computer programs, mental processes, and mathematical formulae were particularly contentious.
See Sterckx & Cockbain, supra note 95, at 40–45.
106
See Sterckx & Cockbain, supra note 95, at 23 (quoting Roger Gajac’s 1955 study on substantive points of
patentability; see also Mitnovetski & Nicol, supra note 79, at 470, 472 (explaining that the concept of ordre public
“expresses concerns about matters threatening the social structures which tie a society together”). Among the
technologies expressly viewed as contrary to the ordre public by the EPO are anti-personnel mines. See Sterckx &
Cockbain, supra note 95, at 57 (providing that at EPC 1973, attendees were told that the EPO believed that inventions
“relating to anti-personnel mines per se should be excluded from patentability as contrary to ‘ordre public’ and
morality”).
107
See Sterckx & Cockbain, supra note 95, at 46–47 (asserting that the German view that medical methods are not
susceptible of industrial application is a “legal fiction”).
108
EPC art. 52(4), supra note 93.
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The EPC entered into effect in July 1978, and the signatory states soon amended their
national patent laws to conform to its requirements. 109 Not all countries, however, adopted the
“industrial application” language justifying the exclusion of medical treatments from patentability.
Denmark, Italy, and Sweden, for example, treated medical treatments as non-inventions, and
Switzerland simply characterized them as legal exceptions to patentable subject matter. 110
Dissatisfaction with the EPC arose soon after its adoption, and negotiations began for its
amendment.111 These negotiations were influenced, 112 among other things, by the negotiation and
ratification of the TRIPS Agreement as part of the World Trade Organization Treaty in 1994 113
and the adoption by the EU of the European Biotechnology Directive of 1998. 114 As part of this
debate, the “fiction” that certain technologies such as medical treatments lacked industrial
application came under fire, largely as part of the larger debate over the patentability of computer
software.115
As a result, in the major amendments to the EPC adopted in 2000, which came into force
in 2007, the exclusion for medical treatments was moved from Article 52, which permitted patents
to be granted on all inventions “susceptible of industrial application,” to Article 53, which included
exceptions for inventions “the commercial exploitation of which would be contrary to 'ordre
public' or morality.”116 In this manner, the idea that medical treatments lacked industrial
application was dispensed with, and it was accepted that the medical treatment exclusion was
intended to serve “the interests of public health.” 117 The final text of the EPC exclusion for medical
treatments, as it exists today, thus reads:
Article 53 – Exceptions to Patentability
European patents shall not be granted in respect of . . . methods for treatment of the
human or animal body by surgery or therapy and diagnostic methods practised on
the human or animal body; this provision shall not apply to products, in particular
substances or compositions, for use in any of these methods. 118
The EPO Boards of Appeal have subsequently confirmed that the exclusion of methods of
medical treatment from patentability is “based on social-ethical and public health
considerations”119 and that “physicians should be free to choose the best medical treatment for a
Mitnovetski & Nicol, supra note 79, at 471–72 (“Shortly after signing the EPC, the member states began adjusting
their legal systems to accord with European uniform law, and article 52(4) was largely adopted.”).
110
Id. at 471.
111
See Sterckx & Cockbain, supra note 95, at 49–65 (tracing the amendments to the EPC, which were born out of
dissatisfaction with the original convention).
112
See id. at 50–59.
113
Agreement on Trade-Related Aspects of Intellectual Property Rights, Including Trade in Counterfeit Goods, Apr.
15, 1994, 1869 U.N.T.S. 299, 33 I.L.M. 881 [hereinafter TRIPS Agreement]. See discussion infra Part II.B (discussing
the medical treatments exclusion under TRIPS).
114
Council Directive 98/44/EC, 1998 O.J. (L 213) 13 (EC).
115
See Sterckx & Cockbain, supra note 95, at 62–65 (outlining various delegations that criticized this idea).
116
See id. at 64–66. These amendments were, in part, enacted to bring the EPC into compliance with the TRIPS
Agreement.
117
See id. at 62–63.
118
EPC art. 53(c), supra note 93.
119
See Decision G 0002/08, 2010 O.J. Eur. Pat. Off. 1; Decision T 0024/91-3.2.02, 1994 O.J. Eur. Pat. Off. 1; Sterckx
& Cockbain, supra note 95, at 157 (“[T]he exclusion of methods of medical treatment has been on societal and ethical
109
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patient without being prevented by exclusive patent rights.” 120 Likewise courts in Europe have
confirmed this focus, holding that “patent law should not interfere with the saving of human life
or the alleviation of human suffering”. 121
C. Methods of Treatment Under TRIPS and Other International Trade Agreements
As discussed above, the EPC establishes certain requirements regarding patent eligibility
among its signatory states. Among these is the Article 53(c) exclusion of patentability for medical
treatments. 122 This approach differs from that taken by the TRIPS Agreement. Negotiations for
the Uruguay round of the General Agreement on Tariffs and Trade (GATT) began in September
1986.123 The treatment of intellectual property rights was always an important part of these
negotiations, and in 1988 a basic framework for the treatment of intellectual property was agreed
among the United States, the EU and Japan. 124 The TRIPS Agreement, which was signed in in
1994 and went into effect in 1995, requires that signatory states provide minimum requirements
for patentability, such as a 20-year term, non-discrimination among subject areas, national
treatment for foreign applications, and the like. 125 In addition, the TRIPS Agreement permits, but
does not require, the exclusion of certain categories of inventions from patent protection. 126 In
particular, TRIPS Article 27(3) provides that signatories may, if they so choose, exclude from
patentability “diagnostic, therapeutic and surgical methods for the treatment of humans or
animals.”127
The TRIPS approach to excluding patentability of medical treatments has been followed
in numerous other multilateral and bilateral treaties, a representative list of which is included in
Appendix A.128 Several trade agreements provide this flexibility simply by referencing Article

grounds rather than on the basis that such methods could not be ‘inventions’”); Stefan Bechtold, Physicians as User
Innovators in Intellectual Property at the Edge x, x (Rochelle Dreyfuss & Jane Ginsburg eds., 2014) (“It is now
widely accepted that the exception of Article 53(c) EPC is primarily driven by ethical, moral, and public health
concerns”).
120
Bechtold, supra note 119, at x (Rochelle Dreyfuss & Jane Ginsburg eds., 2014) (citing European Patent Office,
Tech. Bd. App., University of Manitoba/Lung ventilator device (T 0592/98), at ¶ 2 (2001), http://www.epo.org/lawpractice/case-law-appeals/advanced-search.html; Enl. Bd. App., Cygnus/Diagnostic methods (G 1/04), [2006]
E.P.O.R. 15, 161, 171; Enl. Bd. App., Medi-Physics/Treatment by surgery (G 1/07), [2010] E.P.O.R. 25, 225, 227;
Tech. Bd. App., Wellcome/Pigs 1 (T 116/85), [1988] E.P.O.R. 1, 5).
121
Id. at x (Rochelle Dreyfuss & Jane Ginsburg eds., 2014) (citing, inter alia, Wellcome Foundation Ltd. v. Plantex,
[1979] RPC 514, 540 (Eng.)).
122
EPC art. 53(c), supra note 93.
123
Michael D. Wilkinson, Lobbying for Fair Trade: Northern NGDOS, the European Community and the GATT
Uruguay Round, 17 Third World Q. 251, 251 (1996).
124
Sterckx & Cockbain, supra note 95, at 50.
125
TRIPS Agreement art. 33, supra note 104.
126
Allowing, but not requiring, certain features to be incorporated into national law by signatory states is known as a
treaty “flexibility.” See, e.g., TRIPS Agreement art. 27(2)-(3), supra note 104 (offering several such flexibilities to its
signatories); Laurence R. Helfer, Flexibility in International Agreements, in Interdisciplinary Perspectives on
International Law and International Relations 175, 175 (Jeffrey L. Dunoff & Mark A. Pollack eds., 2013) (“These
[treaty flexibility] provisions function as insurance policies. They provide a hedge against uncertainty that allows a
state to revise, readjust, or even renounce its commitments if the anticipated benefits of treaty-based cooperation turn
out to be overblown.”).
127
TRIPS Agreement art. 27(3), supra note 104.
128
See discussion infra Appendix A.
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27(3) of the TRIPS Agreement, 129 whereas others, such as the Trans-Pacific Partnership (TPP)
Agreement, enumerate this exception expressly. 130
As noted above, the adoption of the medical treatment exclusion under TRIPS Article 27(3)
influenced the negotiation of the EPC and its 2000 amendments.131 It also had a notable impact on
the national laws of many other countries outside of Europe. A recent review of national laws
reveals that more than sixty countries including China, Japan, and India have implemented some
form of statutory patentability exclusion for medical treatments. 132
D. Methods of Treatment in the United States: Statutory Immunity and Patentable Subject
Matter
The handling of medical treatment patents in the United States is somewhat unique and
does not follow the TRIPS model outlined above.133 As noted in Part II.A, the U.S. Patent and
Trademark Office began to allow patents on medical treatment methods in 1954. 134 Yet few
physicians availed themselves of this right or enforced their patents for several decades. This
situation changed in the early 1990s, when ophthalmological surgeon Dr. Samuel Pallin applied
for and received a patent covering a method of sutureless cataract surgery. 135 Shortly thereafter, as
Professor Katherine Strandburg describes, Pallin began to assert the patent and seek royalties from
other eye surgeons including Dr. Jack Singer. 136 Singer refused to acquiesce to Pallin’s royalty
demands and instead marshalled the medical community to oppose not only Singer’s patent, but

129

See, e.g., Trade Promotion Agreement, Colom.-U.S., art. 16.9, Nov. 22, 2006, https://ustr.gov/tradeagreements/free-trade-agreements/colombia-fta/final-text (entered into force May 15, 2012); Agreement, Peru-U.S.,
art.
16.9,
Apr.
12,
2006,
https://ustr.gov/sites/default/files/uploads/Countries%20Regions/africa/agreements/pdfs/FTAs/peru/16%20IPR%20
Legal.June%2007.pdf (“Nothing in this Chapter shall be construed to prevent a Party from excluding inventions from
patentability as set out in Articles 27.2 and 27.3 of the TRIPS Agreement.”).
130
Trans-Pacific Partnership Agreement, art. 18.37, para. 3 (“A Party may also exclude from patentability: (a)
diagnostic, therapeutic and surgical methods for the treatment of humans or animals.”). See Comprehensive and
Progressive Agreement for Trans-Pacific Partnership art. 18.7, Feb. 4, 2016, https://www.mfat.govt.nz/assets/TransPacific-Partnership/Text/18.-Intellectual-Property-Chapter.pdf (incorporating by reference all but 22 of the original
TPP provisions, signed by the TPP countries except the United States, incorporated by reference paragraph 3 of TPP
article 18.37).
131
EPC art. 53(c), supra note 93.
132
Luis Abinader, Review of National Laws Implementing Statutory Patentability Exclusions for Medical Treatments
(Oct. 2018) (unpublished study) (on file with author). See list infra App. B (providing a complete list of these
countries).
133
In fact, some U.S. industry organizations have objected to the implementation of TRIPS flexibilities in this area by
other countries. See, e.g., Pharmaceutical Research and Manufacturers of America (PhRMA) Special 301
Submission 2018 87 (2018), https://www.phrma.org/policy-paper/phrma-special-301-submission-2018 [hereinafter
PhRMA] (arguing that India should be included on a U.S. Department of State list of countries abusing intellectual
property laws because “Section 3(i) of the Indian Patents Act excludes method of treatment claims preventing U.S.
biotechnology companies with needed treatment methods from entering the Indian market and providing life-saving
products”).
134
See discussion supra Part II.A.
135
U.S. Patent No. 5,080,111 (filed June 28, 1990); see Strandburg, Derogatory to Professional Character?, supra note
81, at 328–29 (discussing Pallin’s patent and motivations for seeking it).
136
Pallin v. Singer, No. 2:93-CV-202, 1996 WL 274407 (D. Vt. Mar. 28, 1996) (finding that Pallin’s patent was
invalid and not infringed); see Strandburg, Derogatory to Professional Character?, supra note 81, at 63, 77 (discussing
Pallin’s case against Singer).
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all patents covering medical and surgical techniques. 137 The debate soon reached a national scale
and the American Medical Association issued a report in 1995 concluding that it is unethical for
physicians to “seek, secure or enforce patents on medical procedures.” 138 Despite significant
counter-lobbying by the biotechnology industry, 139 in 1996 Congress added Section 287(c) to the
Patent Act to deal with medical treatment patents. 140
Unlike national statutory schemes that take advantage of the exclusionary flexibilities
under TRIPS, Section 287(c) does not prohibit the patenting of medical treatments outright. 141
Instead, it creates a limited immunity from patent infringement for medical practitioners and
related healthcare entities who practice a patented “medical activity.” 142 There are numerous
exclusions from this immunity, including the use of a patented machine or composition of matter,
the practice of a patented use of a machine or composition of matter, the practice of a process in
violation of a “biotechnology patent,” 143 and the activity of any person engaged in commercial
development of a machine or composition of matter.144 Thus, while the U.S. approach shields
physicians, hospitals, and clinics from liability for performing patented surgical, medical, and
diagnostic procedures, it does not inhibit the enforcement of patents covering medical devices or
drugs or against commercial interests. 145
Despite the immunity granted under Section 287(c), physicians, biopharmaceutical
companies, and medical device manufacturers in the United States continued to obtain patents
covering medical treatments in significant numbers. 146 But in 2012, the Supreme Court cast doubt
on the patentability of certain medical procedures, particularly diagnostic methods, under Section
101 of the Patent Act. In Mayo Collaborative Services v. Prometheus,147 the Court evaluated a
patent that claimed a “method of optimizing therapeutic efficacy for treatment of an immunemediated gastrointestinal disorder.” 148 In creating its now well-known two-part test for patent
eligibility, the Court asked first whether the patent claim in question recited a law of nature and, if
so, whether the claim added enough to qualify as an application of that natural law. 149 With respect
to Prometheus’s claims, the Court held that they merely involved well-understood, routine,

137

See Strandburg, Derogatory to Professional Character?, supra note 81, at 63, 77 (discussing medical community
opposition to medical treatment patents).
138
Proceeding of the House of Delegates, 144 Am. Med. Ass’n 1, 206 (1995), http://www.amaassn.org/ama/pub/about-ama/our-history/ama-historicalarchives/the-digital-collection-historical-amadocuments.page.
139
See Strandburg, Derogatory to Professional Character?, supra note 81, at 63, 77; see also Bradley J. Meier, New
Patent Infringement Liability Exception for Medical Procedures, 23 J. Legis. 265, 265 (2015).
140
Pub. L. No. 104-208, § 616, 110 Stat. 3009 (1996) (codified as amended at 35 U.S.C. § 287(c)).
141
TRIPS Agreement art. 27(2)-(3), supra note 104.
142
A “medical activity” is defined as “the performance of a medical or surgical procedure on a body.” 35 U.S.C.S. §
287(c)(2)(A) (LEXIS through Pub. L. No. 115-391).
143
Id.
144
35 U.S.C.S. § 287(c)(3) (LEXIS through Pub. L. No. 115-391).
145
At least one commentator has argued that the U.S. immunity under Section 287(c) violates the TRIPS Agreement.
See Emily C. Melvin, Note, An Unacceptable Exception: The Ramifications of Physician Immunity from Medical
Procedure Patent Infringement Liability, 91 Minn. L. Rev. 1088, 1089–90 (2007).
146
See, e.g., Aaron K. Chatterji et al., Physician-Industry Cooperation in the Medical Device Industry, 27 Health Aff.
1532, 1535, 1537–38 (2008) (estimating that approximately 20% of medical device patents have at least one physician
inventor).
147
Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 90 (2012).
148
Id. at 74.
149
Id.
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conventional activity previously engaged in by researchers in the field, and thus failed to meet the
threshold for patentability. 150
Much has been made of the uncertainty surrounding Section 101 patent eligibility that
resulted from the Supreme Court’s holding in Mayo and its 2014 decision in Alice v. CLS Bank.151
A number of
U.S. courts have invalidated medical treatment patents under Section 101 after applying
the two-step test established in Mayo. For example, in Mallinckrodt Hospital Prods. IP Ltd. v.
Praxair Distrib., Inc.,152 the court considered the following patent claim:
1. A method of treating patients who are candidates for inhaled nitric oxide
treatment, which method reduces the risk that inhalation of nitric oxide gas will
induce an increase in pulmonary capillary wedge pressure (PCWP) leading to
pulmonary edema in neonatal patients with hypoxic respiratory failure, the method
comprising:
(a) identifying a plurality of term or near-term neonatal patients who have hypoxic
respiratory failure and are candidates for 20 ppm inhaled nitric oxide treatment;
(b) determining that a first patient of the plurality does not have left ventricular
dysfunction;
(c) determining that a second patient of the plurality has left ventricular
dysfunction, so is at particular risk of increased PCWP leading to pulmonary edema
upon treatment with inhaled nitric oxide;
(d) administering 20 ppm inhaled nitric oxide treatment to the first patient; and
(e) excluding the second patient from treatment with inhaled nitric oxide, based on
the determination that the second patient has left ventricular dysfunction, so is at
particular risk of increased PCWP leading to pulmonary edema upon treatment with
inhaled nitric oxide. 153
The court found this claim to be patent ineligible under Section 101 on the basis that the
“core” of the alleged invention, treatment of hypoxic respiratory failure with inhaled nitric oxide,
was a patent ineligible law of nature. 154 And as to whether the claim added anything of significance
to this natural law, the court concluded “Plaintiffs cannot seriously contend that it is a new practice

150

Id. at 77–80.
See Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 573 U.S. 208, 212 (2014) (holding that a computer program for
facilitating complex international financial transactions is an abstract idea that cannot be patented). For critiques of
these decisions, see, e.g., Kevin Madigan & Adam Mossoff, Turning Gold into Lead: How Patent Eligibility Doctrine
is Undermining U.S. Leadership in Innovation, 24 Geo. Mason L. Rev. 939, 950–52 (2017); Dan L. Burk, Dolly and
Alice, 3 J. L. & Biosciences 606, 609–11 (2015).
152
Mallinckrodt Hosp. Prods. IP Ltd. v. Praxair Distribution, Inc., Civil Action No. 15-170-GMS, 2017 U.S. Dist.
LEXIS 142644, at *19 (D. Del. Sept. 5, 2017).
153
Id.
154
Id. at *60.
151
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to exclude certain patients from treatment with a drug when those patients are at an increased risk
of experiencing negative side effects from the drug.” 155 Thus, the claim was not patent eligible. 156
In contrast, the Federal Circuit in Vanda Pharmaceuticals Inc. v. West-Ward
Pharmaceuticals157 held that a method of treating a patient with schizophrenia by determining the
patient’s capacity to metabolize a particular enzyme and then administering a particular dosage of
a drug containing the enzyme based on that finding. 158 Despite the similarity of the method claims
in Vanda to those in Mayo itself, the Federal Circuit held that the claims were not directed to a
natural law or phenomenon.159 According to at least one commentator, “Vanda precipitated a 180degree turn in how district courts deal with patent-eligibility challenges to method of treatment
claims. Whereas pre-Vanda the district courts typically found these claims to be directed to a law
of nature under step one [of Mayo], they now uniformly find them patent-eligible under step one
and do not proceed to step two.” 160
Likewise, the USPTO has issued guidance stating that, consistent with Vanda, "method of
treatment claims that practically apply natural relationships should be considered patent eligible
under Step [1] [of Mayo].”161 Most recently, the Federal Circuit in Endo Pharmaceuticals Inc. v.
Teva Pharmaceuticals USA, Inc. 162 upheld the eligibility of another personalized method of
treatment claim involving the dosing of a particular drug based on a patient’s metabolic
characteristics.
Given these developments, the current trend in the U.S. appears to be to recognize the
patentability of medical treatment claims, subject only to the limited healthcare practitioner
immunity under Section 287(c).
E. Other Jurisdictions and Limits on Patentability of Medical Treatment
In addition to the jurisdictions discussed above, some jurisdictions that have not expressly
adopted statutory limitations on the patenting of medical treatments have limited such patents
through judicial doctrine. In Canada, for example, the Canadian Patent Act does not expressly
exclude medical treatments from patentability. 163 However, the Canadian Supreme Court has
rejected patents covering medical treatments when the claimed method “does not lay in the field
of the manual or productive arts nor, when applied to the human body, does it produce a result in

155

Id. at *54.
Id. at *60.
157
Vanda Pharms. Inc. v. W.-Ward Pharm. Int'l Ltd., 887 F.3d 1117 (Fed. Cir. 2018).
158
Id.
159
Id. Judge Prost dissented from the decision, pointing out the clear analogy to the claims in Mayo. Id. at x.
160
Thomas Hedemann & David Ludwig, Method-Of-Treatment Patent Eligibility: Step 1 And Done? Law360, Feb.
5, 2019.
161
Robert W. Bahr, Recent Subject Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v.
West-Ward Pharmaceuticals (2018).
162
Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2019).
163
See Canada Patent Act, R.S.C. 1985, c P-4 (authorizing the use of a patented invention only if “the Minister of
Health has notified the Commissioner that the version of the pharmaceutical product that is named in the application
meets the requirements of the Food and Drugs Act and its regulations, including the requirements under those
regulations relating to the marking, embossing, labeling and packaging that identify that version of the product as
having been manufactured . . . in a manner that distinguishes it from the version of the pharmaceutical product sold in
Canada by, or with the consent of, the patentee or patentees”).
156
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relation to trade, commerce or industry, or a result that is essentially economic.”164 In effect, this
approach resembles the pre-EPC approach taken by courts in the UK, which found that medical
treatments were not patentable due to their lack of industrial application. 165 The Canadian Patent
Office has adopted this judicial reasoning in its examination procedures and now rejects patent
claims seeking to cover methods that provide a practical therapeutic effect, such as curing,
preventing, or ameliorating an ailment or pathological condition, or treating a physical abnormality
or deformity, such as by physiotherapy or surgery. 166
Likewise, though New Zealand did not statutorily limit the patentability of medical
treatments until recently, 167 the New Zealand courts consistently held that methods of treatment of
human disease do not meet the requirement that patentable methods describe a manner of
manufacture.168
The one developed jurisdiction that appears most willing to grant and enforce medical
treatment patents is Australia. The Australian Federal Court first confirmed the patentability of
medical treatment methods in 1994 in Anaesthetic Supplies v. Rescare and confirmed this result
in 2000 in Bristol Myers Squibb v. F H Faulding.169 The Court’s decision in Bristol Meyers Squibb,
a case involving a method of administering the anti-cancer drug Taxol, is particularly telling. In
that case, the lower court, relying on a dissenting opinion in Rescare, held that issuing a patent on
the claimed treatment method was “generally inconvenient” under the public policy proviso of the
Australian Statute of Monopolies, and that the patent was thus invalid. 170 The Federal Court
unanimously reversed the lower court’s decision, finding no reason to deviate from its prior
reasoning in Rescare. Most recently, an Australian High Court again confirmed the patentability
of methods of treatment involving the administration of therapeutic drugs in Apotex v. SanofiAventis Australia.171 Interestingly, each of these decisions involved method claims describing the
administration of a therapeutic agent or drug. The Australian courts have yet to confirm the
patentability of purely medical or surgical procedures.172

164

Apotex Inc. v. Wellcome Found. Ltd. [2002] S.C.R. 153 (Can.) ("The policy rationale . . . was that the unpatentable
claim was essentially non-economic and unrelated to trade, industry, or commerce. It was related rather to the area of
professional skills."); Tennessee Eastman v. Commissioner of Patents [1974] S.C.R. 111 (Can.); Commissioner’s
Decision,
No.
197,
at
2
(1974)
(Can.),
http://brevets-patents.ic.gc.ca/opiccipo/comdec/eng/decision/194/image.html?page=1&scale=0.25&rotation=0 ("Having come to the conclusion that
methods of medical treatment are not contemplated in the definition of ‘invention’ as a kind of ‘process’”).
165
David Letham & Richard Scott, The Doctrine of Equivalents Reaches the UK 1–2 Hoffmann Eitle,
https://www.hoffmanneitle.com/wp-content/uploads/The-Doctrine-Of-Equivalents-Reaches-the-UK.2-1.pdf.
166
Can. Intell. Prop. Off., Patent Office Manual of Patent Office Practice (2018),
https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/vwapj/rpbb-mopop-eng.pdf/$file/rpbb-mopop-eng.pdf
(explaining that section 17.03.01 notes, however, that “removal of the medical aspect of a claim may render [the claim]
acceptable”).
167
Patents Act 2013, s 2 (N.Z.) (“An invention of a method of treatment of human beings by surgery or therapy is not
a patentable invention.”).
168
Swift & Co. [1960] NZIPOPAT 1 (1960) (N.Z.); Wellcome Found. Ltd. v. Comm’r of Patents [1983] NZCA 385
(N.Z.); Susy Frankel, Intellectual Property in New Zealand and the TPPA 173–74 (Victoria Univ. of Wellington,
Legal Research Paper No. 37, 2012) (“The Patent Bill before Parliament at the time of writing includes some
exceptions to patentability because these things should not be the exclusive property of anyone.”).
169
Bristol-Myers Squibb Co. v. F H Faulding & Co. Ltd. [2000] FCA 316 (22 March 2000) ¶¶ 132–39 (Austl.).
170
Id. ¶¶ 5–7.
171
Apotex Pty. Ltd. v. Sanofi-Aventis Australia Pty. Ltd. [2013] HCA 50 (4 December 2013) (Austl.).
172
It is important to note that medical treatments are not always patentable under Australian law. Each patent claim
must be addressed on a case-by-case basis. See, e.g., id.
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F. Summary: Methods of Medical Treatment Patentability Exclusions
As shown in this Part II, numerous jurisdictions have limited the ability of applicants to
obtain patents on methods of medical treatment. The EPC expressly removes medical treatments
from patentability and has been followed by all EPC member states. 173 The TRIPS Agreement and
numerous other bilateral and multilateral trade agreements allow signatory states to exclude
medical treatments from their national patent laws, and at least sixty states have taken advantage
of this flexibility to do so. 174 The United States, in contrast, has adopted a unique statutory
immunity from infringement for medical practitioners and healthcare organizations, but it
otherwise likely to uphold patents on medical treatments. Other countries, though they have not
enacted specific legislation limiting medical treatment patents, have taken a range of judicial
positions that have failed to uphold such patents on grounds of lack of industrial application. As a
result, the patentability of medical treatments is effectively prohibited or limited throughout much
of the developed world.
III. ARE CAR-T AND OTHER GENE THERAPIES PATENTABLE?
Given the extensive limitations on patenting medical treatments around the world, we ask
whether CAR-T and other gene therapies discussed in Part I should be considered medical
treatments subject to such limitations. In analyzing this question, it is important first to develop a
more detailed understanding of the definition “medical treatment.” While we are unaware of any
court or agency decision applying this definition specifically to CAR-T therapies, several useful
discussions exist in the case law and literature.
A. Methods of Medical Treatment under the EPC Exclusion
As described in Part II.B, Article 53(c) of the EPC excludes medical treatments from patent
protection on grounds of ordre public and morality.175 Over the years, the courts and the European
Patent Office (EPO), including the EPO’s Boards of Appeal, 176 have interpreted the Article 53(c)
exclusion (including its precursor under Article 52[4]) and its subcomponents. In this Part III.A,
we discuss the decisions of these bodies inasmuch as they are relevant to the patentability of gene
and cell therapies, which we take up specifically in Part III.B, below. 177

173

EPC art. 53(c), supra note 93.
World Intellectual Prop. Org. [WIPO], Exclusions from Patentable Subject Matter and Exceptions and Limitations
to the Rights, at 58, WIPO Doc. SCP/15/3 (Jan. 1, 2010); Mitnovetski & Nicol, supra note 79, at 470.
175
Mitnovetski & Nicol, supra note 79, at 472.
176
Decisions of the EPO are reviewed by one of twenty-eight Technical Boards of Appeal, with appellate recourse to
an Enlarged Board of Appeal. See About the Boards of Appeal, Eur. Pat. Off., https://www.epo.org/lawpractice/case-law-appeals/about-the-boards-of-appeal.html (last visited Feb. 12, 2019). Decisions of the EPO are not
strictly binding on national courts, which have the ultimate authority to interpret their national patent statutes and to
assess the patentability of inventions under those statutes. However, decisions of the EPO, and its Board of Appeal in
particular, are viewed as highly informative to national courts interpreting their national laws implementing the EPC.
177
For a comprehensive discussion of the EPC’s medical treatment exclusion, see Sterckx & Cockbain, supra note
95, at 135–71.
174
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1. Performance by a Medical Practitioner
The EPO Boards of Appeal have defined the term “medical treatment” as “any noninsignificant intentional physical or psychic intervention performed directly or indirectly by one
human being—who need not necessarily be a medical practitioner—on another . . . using means
or methods of medical science.” 178 The Boards of Appeal have explained that a medical treatment
need not be carried out by a physician in other to fall within the exclusion. 179 However, the Boards
have also suggested that there is a strong presumption that a method is excluded under the EPC
when that method has to be performed by a physician or under his or her supervision. 180
2. Practiced on the Human Body
To fall within the exclusion provided under EPC Article 53(c), the method of treatment
must be “practised on the human or animal body.” 181 However, Article 53(c) “does not require a
specific type and intensity of interaction with the human or animal body.” 182 According to the EPO
Boards of Appeal, a method claim falls under the prohibition if it includes at least one feature
defining a physical activity or action that constitutes a method step for treatment of the human or
animal body by surgery or therapy. 183 Indeed, according to the EPO Boards of Appeal, “[T]he
surgical or therapeutic nature of a method claim can perfectly be established by a single method
step . . . .”184 This “single step” threshold is also recognized in the November 2018 edition of the
EPO Guidelines for Examination. 185

178

Case T 0182/90 (Blood flow), ECLI:EP:BA:1993:T018290.19930730, ¶ 2.2 (July 30, 1993),
https://www.epo.org/law-practice/case-law-appeals/recent/t900182ex1.html.
179
Id.; see Sterckx & Cockbain, supra note 95, at 156.
180
Case T 0024/91 (Cornea), ECLI:EP:BA:1994:T002491.19940505, ¶ 2.4 (May 5, 1994), https://www.epo.org/lawpractice/case-law-appeals/recent/t910024ex1.html (“[W]here, in view of the health risks connected with such a
treatment, a claimed method for treatment has to be performed by a physician or under his supervision, it will normally
fall within the exclusion of the first sentence of Article 52(4) EPC.”); Case T 0329/94 (Blood extraction method),
ECLI:EP:BA:1997:T032994.19970611, ¶ 5 (June 11, 1997), https://www.epo.org/law-practice/case-lawappeals/recent/t940329ex1.html (“This sole criterion is not sufficient to decide whether the method step is
objectionable under Art. 52(4) EPC, though the medical competence of the practitioner may be, at first sight, a useful
indication. Much more important are the purpose and inevitable effect of the feature under consideration.”).
181
Guidelines for Examination in the European Patent Office, Eur. Pat. Off., at Part G, ch. 2, § 4.2.1 (2018),
http://documents.epo.org/projects/babylon/eponet.nsf/0/2A358516CE34385CC125833700498332/$File/guidelines_
for_examination_2018_hyperlinked_en.pdf.
182
See, e.g., Case G 0001/04 (Diagnostic methods), ECLI:EP:BA:2005:G000104.20051216, ¶ 6.4.2 (Dec. 16, 2005),
https://www.epo.org/law-practice/case-law-appeals/recent/g040001ex1.html (“It follows that each and every one of
these method steps satisfies the criterion ‘practised on the human or animal body’ if its performance implies any
interaction with the human or animal body, necessitating the presence of the latter.”).
183
Id. This principle is known as the “contamination” approach, as any single medical treatment step will
“contaminate” the entire claim and render it unpatentable. Sterckx & Cockbain, supra note 95, at 159 (“To have done
otherwise would have made a mockery of the exclusion—if cutting off a man's leg is surgery, then does giving him a
cup of tea afterwards mean he has not undergone surgery?”).
184
See Case G 0001/04 (Diagnostic methods), ECLI:EP:BA:2005:Gooo104.20051216, at ¶ 6.2.1; see also G 2/08,
O.J. EPO 2010, 456 at 476, ¶ 5.6. (“[A]ny method claim containing even a single step pertaining by nature to a
treatment by therapy is not allowable. This is established case law.”).
185
Guidelines for Examination in the European Patent Office, supra note 168, at Part G, ch. 2, § 4.2.1.
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However, claims that disclose methods carried out fully in vitro, without requiring that at
least one of the steps be practiced on the human or animal body, do not fall within the Article 53(c)
exception.186 Thus, as explained by Sterckx and Cockbain,
It has long been clear that ex vivo diagnostic methods (e.g. diagnostic tests
performed on blood samples) as well as the substances and equipment used by
physicians and veterinary surgeons in the course of diagnosis, therapy and surgery,
were not and are not excluded from patentability. 187
3. Surgery or Therapy
In order to be excluded from patentability, Article 53(c) requires that the method of
treatment be implemented by means of “surgery or therapy.” 188 Several forms of medical
intervention have been considered by the EPO Boards of Appeal to fall within the meaning of the
term “therapy” for purposes of applying this exception. The Board has applied this exception to
patent applications claiming curative therapies, or methods for the healing of diseases, 189 but also
for methods aimed at relieving pain, or symptomatic therapy,190 and methods designed to prevent
diseases from occurring, also known as prophylactic therapy. 191
4. Removal from the Body
The EPO Guidelines for Examination explain that the treatment of body tissue or fluids
“after they have been removed from the human or animal body, or diagnostic methods applied
thereon, are not excluded from patentability as long as these tissues or fluids are not returned to
the same body.”192 By the same reasoning, the treatment of body tissue or fluids that are returned
to the same body are subject to the exclusion contained in Article 53(c). 193 An example given by
the EPO Guidelines involves fluids removed from the body: the treatment of blood for storage in
a blood bank or diagnostic testing of blood samples are generally not excluded from patentability,
while the treatment of blood by dialysis with the blood being returned to the same body, are
generally excluded from patentability under Article 53(c).194 Accordingly, it is the return of tissues
or fluids to the same body from which they were originally taken that bring a process within the
patentability exclusion of Article 53(c). 195

Case G 0001/04 (Diagnostic methods), ECLI:EP:BA:2005:G0001045.20051216, ¶ 6.4.3. (“[T]his criterion is
neither complied with in respect of method steps carried out in vitro in a laboratory.”).
187
Sterckx & Cockbain, supra note 95, at 158.
188
See id. at 138–52 (discussing cases defining therapy and surgery).
189
Case T 0019/86 (Pigs II), ECLI:EP:BA:1987:T001986.19871015, ¶ 8 (Oct. 15, 1987), https://www.epo.org/lawpractice/case-law-appeals/recent/t860019ep1.html.
190
Case T 0081/84 (Dysmenorrhea), ECLI:EP:BA:1987:T008184.19870515, ¶ 4 (May 15, 1987),
https://www.epo.org/law-practice/case-law-appeals/recent/t840081ex1.html.
191
See Case T 0019/86 (Pigs II), ECLI:EP:BA:1987:T001986.19871015, ¶ 7.
192
Guidelines for Examination in the European Patent Office, supra note 168, at Part G, ch. 2, § 4.2.1.
193
Id.
194
Id. (“Thus the treatment of blood for storage in a blood bank or diagnostic testing of blood samples is not excluded,
whereas a treatment of blood by dialysis with the blood being returned to the same body would be excluded.”).
195
Id.
186
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5. Product versus Process Claims
Much of the controversy surrounding medical treatment patents has arisen with respect to
methods of administering particular drugs (i.e., patient selection, dosing regimen, etc.). While
Article 53(c) of the EPC prohibits the patenting of medical treatments, it expressly does not apply
to “products, in particular substances or compositions, for use in any of these methods.” 196 As
explained by the EPO Enlarged Board of Appeals,
The provisions of Article 53(c) EPC are clear and unambiguous, drawing a
borderline between unallowable method claims directed to a therapeutic treatment
on the one hand and allowable claims to products for use in such methods on the
other hand . . . [Thus,] in respect of claims directed to therapy, method claims are
absolutely forbidden in order to leave the physician free to act unfettered, whereas
product claims are allowable provided their subject-matter be new and inventive. 197
Despite the seeming clarity of this distinction, the division between treatment methods and
products became blurred in the case of patent claims covering methods for the administration of
particular drugs, especially drugs that were themselves unpatented. 198 This issue was addressed, to
a degree, in the 2000 amendments to the EPC, which added Article 54(5) providing that methods
of treatment involving a new use of a known substance were amenable to patent protection,
notwithstanding the limitations of Article 53(c). 199 The EPO Enlarged Board of Appeal has since
clarified that such new uses can encompass any “specified new and inventive therapeutic
application” (e.g., new dosage regimes) and need not be drawn to entirely new diseases than the
substance was previously known to address. 200
B. Applying the EPC Patentability Exclusion to Gene Therapies
Article 53(c) of the EPC has important implications for the patentability of gene and cell
therapies at the EPO. In this Part, we analyze the features of CAR-T patent claims in view of the
patentability exclusion under EPC Article 53(c) and conclude that such claims are largely
encompassed by this exclusion. It seems that we are not alone in this assessment: even
196

EPC art. 53(c), supra note 93.
See G 2/08, OJ EPO 2010, at 477, ¶ 5.7.
198
Carlos Correa, Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health
Perspective
–
A
Working
Paper
16
(Jan.
27,
2007),
http://apps.who.int/medicinedocs/documents/s21419en/s21419en.pdf.
199
EPC art. 54(5), supra note 93 (“Paragraphs 2 and 3 [relating to novelty] shall also not exclude the patentability of
any substance or composition [comprised in the state of the art] for any specific use in a method referred to in Article
53(c), provided that such use is not comprised in the state of the art.”). See Sterckx & Cockbain, supra note 95, at
159.
200
See G 2/08, OJ EPO 2010, at 485, ¶ 5.10.5. Prior to the 2000 EPC amendments and the EPO Enlarged Board of
Appeal’s decision in G 0002/08, many applicants drafted claims for new uses of known substances in terms of a
manufacturing process for the substance (so-called “Swiss-type claims”). The Board eliminated the permissibility of
such Swiss-type claims in G 0002/08 given the clarified language of EPC Article 54(5). G 2/08, OJ EPO 2010, at 492,
¶ 7.1.3.
197
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representatives of the biopharmaceutical industry appear to recognize that gene and cell therapies
such as CAR-T are better characterized as medical procedures than drugs, which then leads to the
question of what type of intellectual property protection, if any, applies. During a panel of the Fifth
Global Congress on Intellectual Property and the Public Interest, Joseph Damond, Senior Vice
President of the Biotechnology Industry Organization (BIO), stated:
What I'm concerned about, then, is not just where we stand now, but where the
future of the industry is going. Because, if you look at those pipelines, what's being
done right now are things like gene therapy and cell therapy, where you take your
blood and give it to a company and they modify your DNA to correct for mutations
and they give it back to you, which looks more like a service, actually, than a drug.
And what's the IP on that?201
The remainder of this Part explores this question.
1. In vivo versus in vitro procedures
Gene therapies involve introducing, removing or changing the content of a person’s genetic
Cell therapy involves administering living cells to a patient. 203 Therefore, patent claims
covering gene and cell therapies are often drafted using methods claims where at least one of the
steps is performed in vivo.204 In such cases, these method claims, including methods of performing
CAR-T therapy, can be considered methods “practiced on the human or animal body,” therefore
falling under the exclusion provided in EPC Article 53(c).205
code.202

Although gene and cell therapies, including CAR-T, may also involve ex vivo steps in
which genes and cells are harvested or modified outside the human body, EPC Article 53(c) does
not require all of the method steps to be practiced on the patient in order to be considered a method
of treatment.206 As the EPO Boards of Appeal has explained, “the surgical or therapeutic nature of
a method claim can perfectly be established by a single method step . . . .” 207
It is precisely one of the method steps, the reintroduction of the cells to the same patient
from which they were previously extracted, that better illustrate why CAR-T method patent
applications likely fall under EPC Article 53(c). As noted in Part II.A.4 above, the EPO Guidelines
distinguish between methods that only involve extracting body tissues or fluids from methods that

O’Neill Institute, Global Congress on Intellectual Property & The Public Interest, YouTube (Oct. 10, 2018),
https://www.youtube.com/watch?v=OkuSLYIxqbg&feature=youtu.be&t=2175.
202
Gene and Cell Therapy Defined, Am. Soc’y Gene & Cell Therapy, https://www.asgct.org/education-legacy/geneand-cell-therapy-defined (last visited Feb. 13, 2019).
203
Id.
204
Gregory Ramina, Regulation and Oversight of Gene Therapy in the US, Regulatory Focus 2 (Feb. 2017),
https://advanced.jhu.edu/wpcontent/uploads/2017/03/gregoryRamina_regulationAndOversightOfGeneTherapyInTheUS.pdf.
205
EPC art. 53(c), supra note 93; Ramina, supra note 191, at 2.
206
EPC art. 53(c), supra note 93; Ramina, supra note 191, at 2.
207
Case G 0001/04 (Diagnostic methods), ECLI:EP:BA:2005:G000104.20051216, ¶ 6.4.3 (Dec. 16, 2005),
https://www.epo.org/law-practice/case-law-appeals/recent/g040001ex1.html.
201
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also involve reintroducing the extracted tissues or fluids to the same patient, such as dialysis. 208
The last example closely resembles the apheresis and cell infusion steps that are required in CART therapies.209
Despite the original focus of CAR-T patents on compositions of matter, 210 there are
numerous examples today of EPO applications for CAR-T and other gene therapies that read in
terms of methods of treatment. For example, one claim of a 2014 PCT application submitted by
Dr. Carl June, a CAR-T pioneer at the University of Pennsylvania, reads as follows:
A method for inducing at least a first and second epitope-specific immune response
in a cancer patient, the method comprising administering to a patient in need thereof
an effective amount of a cell genetically modified to express a chimeric antigen
receptor (CAR) comprising an antigen binding domain, a transmembrane domain,
and an intracellular signaling domain, wherein the first epitope-specific immune
response is directed to a target epitope recognized by the CAR. 211
This claim encompasses (a) a method (b) for inducing an immune response (c) by
administering a cell genetically modified to express a CAR, and (d) a description of the cell. 212
As such, this claim appears highly susceptible to interpretation as a method of medical treatment.
There is at least one EPO application disclosing a CAR in which the examiner raised
Article 53(c) objections against two of the claims. 213 The first EPO opinion for this application
rejected the claims, reasoning that:
Claims 18 and 19 refer to a method of modulating the activity of a T lymphocyte
in vivo. This is considered as a method of treatment practiced on the human or
animal body. Pursuant to Art. 53(c) EPC, the subject-matter of said claims is not
regarded as being patentable. Consequently, said claims should be either deleted or
reformulated appropriately. 214

208

Guidelines for Examination in EPO, supra note 168, at Part G, ch. 2, § 4.2.1.
What is the Process of Getting Treated with CAR T Cell Therapy?, Be The Match: CAR T Cell Therapy,
https://bethematch.org/patients-and-families/about-transplant/clinical-trials/car-t-cell-therapy/ (last visited Feb. 15,
2019).
210
See infra note 215 and accompanying text.
211
U.S. Patent Application No. 14/409,798 claim 1 (published Aug. 18, 2016).
212
Id. (claiming that an effective amount of genetically modified cells needs to be administered to the patient to express
a CAR).
213
European Patent Specification, European Patent Office App. No. 14751227.1, Publication No. EP2 956175B1, at
3 (published Oct. 4, 2017).
214
Examination, European Patent Office App. No. 14751227.1, ¶ 5.1 (filed on Mar. 22, 2016),
https://register.epo.org/application?number=EP14751227&lng=en&tab=doclist (select “Search/examination” in drop
down menu and then scroll down to find a document dated “25.07.2016” and titled “European search opinion”).
209
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Following this opinion, the applicant amended its claims to eliminate the term in vivo and
replaced it with the term in vitro.215 After these changes, the application was allowed. 216 It appears
that, in the opinion of the examiner, amending the claims to suggest that that specific step of the
method was conducted “in vitro” as opposed to “in vivo” was sufficient to avoid the “practised on
the human . . . body” threshold of Article 53(c). 217 This reasoning appears questionable. Clearly,
whatever alterations are made to the patient’s T-cells outside of the body, the cells must eventually
be returned to the patient’s body to be effective. As such, the CAR-T process described in the
claims more closely resembles a procedure like dialysis (in which cells are treated and then
returned to the body) than storage of cells for biobanking (in which cells are removed from the
body and not returned). 218 Simply diverting attention to the in vitro aspect of the procedure does
not eliminate all of its in vivo elements and, as noted above, only one in vivo step of a process is
required in order to classify it as a medical treatment.219
2. Process versus Product
Another question regarding the applicability of Article 53(c) to CAR-T and other gene
therapies is whether such technologies are more likely to be classified as treatments or products.
As noted in Part II.B.5 above, the patentability exclusion of EPC Article 53(c) does not apply to
therapeutic compounds or substances, a compromise reached during the negotiation of the EPC to
preserve the patentability of pharmaceutical products.220 But as discussed above in this Part III.B,
CAR-T and other gene therapies resemble medical treatments in many ways: they are designed to
treat disease by taking action on a patient’s body through the removal, treatment, and replacement

215

Claim 18 and 19 of EPO patent application EP2956175 currently reads as follows:
“18. A genetically modified cell according to claim 10 or 11 for use in a method of treatment of a cancer in an
individual, wherein the conditionally active CAR is specific for an epitope on a cancer cell in the individual, and
wherein the method comprises: i) introducing the genetically modified cell into the individual; and ii) administering
to the individual an effective amount of a dimerizing agent, wherein the dimerizing agent induces dimerization of the
heterodimeric, conditionally active CAR, wherein said dimerization provides for activation of the genetically modified
cell and killing of the cancer cell, thereby treating the cancer.”
“19. A method of modulating the activity of a T lymphocyte host cell, the method comprising contacting the host cell
in vitro or ex vivo with a dimerizing agent and a second member of a specific binding pair, wherein the T lymphocyte
is genetically modified to produce a heterodimeric, conditionally active CAR of any one of claims 1 to 9, and wherein,
in the presence of the dimerizing agent and the second member of a specific binding pair, the heterodimeric,
conditionally active CAR dimerizes and modulates at least one activity of the host cell.” European Patent
Specification, European Patent Office App. No. 14751227.1, supra note 200, at 149.
216
See Communication under Rule 71(3) EPC, European Patent Office App. No. 14751227.1, Ref. No.
AHB/FP7144538 (May 9, 2017).
217
Id.; EPC art. 53(c), supra note 93.
218
European Patent Specification, European Patent Office App. No. 14751227.1, supra note 200, at 149 (stating that
a genetically modified cell is introduced into the individual’s body as treatment for the cancer).
219
Furthermore, even in their current form, the application still appears to claim steps that likely consist of a method
of treatment, even if it now does not use the term “in vivo.” That is the case, for example, with the phrase “introducing
the genetically modified cell into the individual” as provided in the current version of the claims. European Patent
Office Application No. 14751227.1, supra note 200, at 149. See Sherkow et al., supra note 16 (("our definition [of
gene therapy] is agnostic as to whether such modification takes place inside patient’s body or, as with CAR-T, outside
of it").
220
See Guidelines for Examination in the European Patent Office, supra note 168, at Part G, ch. 6, § 7.1.2; see also
discussion supra Part II.B.5.
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of the patient’s own cells. 221 In this regard, such therapies resemble dialysis and other medical
procedures that are generally acknowledged as excluded from patentability under Article 53(c). 222
In fact, Kite Pharma, the developer of Yescarta, explicitly describes its patents as covering
“methods of treatment” in its public securities filings.223
However, in their regulatory filings, the developers of CAR-T therapies have gone to great
lengths to refer to these therapies not as medical treatments, but as products. For example, as
discussed in Part I.C, both the U.S. FDA and the EU EMA give considerable weight to the
“manufacturing” practices proposed for new gene therapies. 224 Novartis, in its FDA application
for marketing approval of Kymriah, consistently refers to Kymriah (tisagenlecleucel) as a
“product” that is “manufactured” at a facility in New Jersey, 225 much as a traditional drug would
be. The documentation published by the European Medicine Agency (EMA) also describes
Kymriah as a “product.”226
This characterization of Kymriah as a product or drug, however, is a fiction. 227 The
“product” in question is a batch of the patient’s own T-cells that are taken from the patient, altered,
and then re-introduced into the patient’s body. 228 This is not a manufactured product, but a process
performed ex vivo on the patient’s cells. 229
The “labeling” of a “product” like Kymriah pushes this fiction to its limit, as the “product”
in question is not sold or marketed to the public, patients, pharmacists, or physicians, but rather is
extracted from a particular individual for eventual re-introduction to the donor individual alone,
and to no one else. 230 As such, the “packaging” in which Kymriah is approved to be “marketed” is
the intravenous infusion bag used to reintroduce the modified T-cells to the patient’s body. 231 This
See Chimeric Antigen Receptor (Car) T- Cell Therapy, Leukemia and Lymphoma Soc’y,
https://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy (last
visited Feb. 17, 2019); see also discussion supra Part III.B.
222
What is CAR-T Cell Therapy?, Penn. Medicine: Abramson Cancer Ctr. (Dec. 4, 2017),
https://www.pennmedicine.org/cancer/about/focus-on-cancer/2017/december/defining-cart;
Guidelines
for
Examination in the European Patent Office, supra note 168, at Part G, ch. 2, § 4.2.1.
223
Kite Pharma, Inc., Annual Report (Form 10-K) 16 (Feb. 28, 2017) (“Our intellectual property estate strategy is
designed to provide multiple layers of protection, including: (1) patent rights with broad claims directed to core CAR
constructs used in our products; (2) patent rights covering methods of treatment for therapeutic indications; (3) patent
rights covering specific products; and (4) patent rights covering innovative manufacturing processes, preconditioning
methods, new constructs and methods for genetically engineering T cells.”) (emphasis added).
224
Richard Kingham et al., Biological Drug Products: Development and Strategies 85, 92 n.65, 97–98 (Wei
Wang & Manmohan Singh eds., 2014).
225
Novartis Approval Letter, supra note 3, at 1.
226
European Medicine Agency [EMA], Annex I: Summary of Product Characteristics, at 2,
https://www.ema.europa.eu/documents/product-information/kymriah-epar-product-information_en.pdf (last visited
Feb. 17, 2019).
227
We recognize that the tendency for manufacturers to characterize their gene therapies as “products” is also due to
the statutory authority of the FDA, which regulates products and their manufacture, but not medical procedures. But
even if there is an extrinsic reason pushing manufacturers to categorize these methods as products, the classification
is still, in our view, a fiction.
228
See id. at 39 (describing the process of how the doctor will remove the patient’s white blood cells, process them to
make Kymriah, and then return the substance to the patient’s body).
229
Id. at 2. This being said, we recognize that the producers of CAR-T and other gene and cell therapies have drafted
some of their patent claims to cover modified T-cells and other biological compounds as compositions of matter.
While these types of claims might appear to avoid exclusion under the medical treatment provisions discussed in this
article, we suggest that the examining patent offices look past artful claiming to the actual invention for which a patent
is sought—in this case, a method of medical treatment.
230
See id. at 36, 39 (explaining the unique characteristics of Kymriah and how the product is formed).
231
See id. at 39 (describing how Kymriah will be stored and labeled).
221
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is hardly “marketing” of a product, given that no individual—patient, pharmacist, or physician—
need make any purchasing or prescribing decision regarding the re-administration of the modified
T-cells back to the patient. 232 Thus, referring to a CAR-T therapy such as Kymriah as a product
that is packaged and marketed simply mischaracterizes the nature of the therapy and inaccurately
conflates it with a drug product that is marketed and prescribed to members of the public. While
this characterization appears to be acceptable to the FDA and EMA which encourages applicants
to apply the language of “products” to new gene therapies in its Guidance documents, 233 this
peculiar regulatory approach should not alter the more accurate characterization of such gene
therapies as medical treatments under the patent laws, which stand quite apart from the
requirements for regulatory marketing approval.
C. CAR-T and Gene Therapies Beyond the EPC
As discussed in Part III.B above, CAR-T and other gene and cell therapies should most
likely be classified as medical treatments under the EPC and thus excluded from patentability
under EPC Article 53(c). By the same token, such therapies should also be excluded from
patentability under other legal regimes that exclude patents on medical treatments, including (a)
national implementations of EPC Article 53(c), (b) national patent laws that implement the
flexibility to exclude such patents under TRIPS Article 27(3) and other bilateral and multilateral
trade agreements, and (c) judicial precedents, such as those in Canada and New Zealand, that
exclude patentability of medical therapies as lacking industrial application or as against ordre
public and morality. In addition, in the United States CAR-T and other gene and cell therapies
should trigger the immunity from infringement for physicians and healthcare organizations under
Section 287(c) of the U.S. Patent Act.
Admittedly, outside of the EPC and U.S., there is little case law or agency guidance
regarding the scope of the medical treatment exemption, and even less that informs its application
to gene and cell therapies. However, we believe that the detailed reasoning of the EPO and its
Boards of Appeal described in Part III.A is particularly useful even to jurisdictions that are outside
of the EPC.234 In fact, certain non-EPC legal regimes may offer national patent offices and courts
even greater latitude to exclude patents covering medical treatments than does the EPC. For
example, EPC Article 53(c), coupled with Article 54(5), creates an express carve-out for medical
treatments that involve the application of a novel application of a known drug. But this carve-out
does not exist in the TRIPS Agreement, 235 and TRIPS member states that have elected to exclude
patentability of medical treatments may do so unreservedly, without permitting patents on
treatments that involve a drug. 236

See id. at 36 (explaining how T cells are removed from your body, modified, and then placed back in a patient’s
body for the purpose of destroying cancer cells).
233
See INDs Information, supra note 31, at 1–2.
234
See discussion supra Part III.A.
235
See TRIPS Agreement art. 27, supra note 104.
236
See Michael H. Davis, Excluding Patentability of Therapeutic Methods, Including Methods Using Pharmaceuticals,
for the Treatment of Humans Under Trade Related Aspects of Intellectual Property Rights Article 27(3)(A), 43
Hofstra L. Rev. 185, 185–86 (2014).
232
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IV. IMPLICATIONS AND OUTLOOK
In Part III above we conclude that under the legal standards prevailing in Europe, the
United States, and numerous other countries, CAR-T and other gene and cell therapies can be
classified as medical treatments that are not subject to patent protection. In this Part, we examine
the implications of this finding both for current practice and future developments.
A. Existing CAR-T Patents: Post-Grant Challenges
As noted in Part II.C above, numerous patents have been issued, and many more
applications have been filed around the world, to protect CAR-T and other gene and cell therapies.
If the analysis contained in Part III is correct, then many, if not all, of these patents are contrary to
existing statutory exclusions of patentability under the EPC and similar statutory regimes. 237 As
such, it is likely that when the owners of such patents assert them in litigation, they would be
subject to successful invalidity defenses by the alleged infringers. 238
However, even if such patents could successfully be challenged in litigation, the existence
of such patents “on the books,” even if invalid, can itself significantly impact private behavior and
chill productive research and development of competing products. The situation is complicated
further if medical treatment patents are included in larger patent portfolios that include both
medical treatment patents as well as patents covering drugs or medical devices that are not barred
by medical treatment patentability exclusions. For all of these reasons, there is a recognized public
interest in clearing the market of invalid patents.239
There are several existing mechanisms by which patents may be challenged after grant. In
Europe, issued patents may be challenged in an opposition proceeding under Article 99 of the
EPC.240 Article 99 provides that “any person” may file an opposition seeking to invalidate an
issued European patent within nine months of its publication in the European Patent Bulletin. 241
In addition to lack of disclosure and patents granted with a subject-matter that extends beyond the
content of the application as filed, EPO oppositions can be filed when the patent is not patentable
under Articles 52 to 57 of the EPC, which of course includes Article 53(c) regarding medical
treatments.242
Issued patents may also be challenged in the United States using a number of procedures
before the Patent Trial and Appeals Board (PTAB), including post-grant review (PGR)243 and inter
partes review (IPR).244 However, neither PGR nor IPR proceedings are relevant vehicles for
asserting the medical practitioner immunity granted under Section 287(c) of the Patent Act (as this

237

Guidelines for Examination in the European Patent Office, supra note 168, at Part G, ch. 2, § 4.2.1.
Id.
239
See Lear, Inc. v. Adkins, 395 U.S. 653, 670 (1969) (recognizing an “important public interest in permitting full
and free competition in the use of ideas which are in reality a part of the public domain”).
240
EPC art. 99, supra note 93.
241
Given the recent advent of CAR-T and other gene and cell therapies, we estimate that most patent applications
covering these technologies are still being examined at the EPO, and in most cases, the nine-month deadline to file
oppositions against prospective patents has not been triggered. Id.
242
Id.
243
35 U.S.C. § 321 (2017).
244
§ 311.
238
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immunity is a defense to a claim of infringement rather than a challenge to an asserted patent). 245
Thus, in the United States, the only viable means for challenging the enforcement of medical
treatment patents is likely to be an immunity defense under Section 287(c).
Traditionally in the United States, Europe, and elsewhere, only a patentee’s direct
competitors have had sufficient incentives to monitor and challenge patents in oppositions and
other post-grant proceedings. 246 However, recent years have seen the emergence of public
watchdog entitles such as Unified Patents that raise funding to challenge questionable patents in a
range of technology markets (e.g., mobile devices, automotive technology, Internet of Things,
etc.).247 Given that the cost of mounting an opposition or post-grant challenge to patents is
significantly lower than the cost of patent litigation in general, it is possible that entities may
emerge to challenge questionable patents in the gene and cell therapy sector as well, at least in
Europe and other jurisdictions in which the validity of such patents is in doubt. 248
B. Future Examination Guidance
Given the recent advances in CAR-T and other gene and cell therapies, patents covering
these techniques are still relatively young. Thus, while there are comparatively few issued patents
covering these techniques today, a large number of patent applications is likely pending in the
examination process around the world, a number that is likely to increase over time. If such
techniques are not eligible for patent protection under applicable statutory and judicial limitations
on patentability of medical treatments, then it would be far more efficient for examining patent
offices to deny the issuance of patents on such claims, rather than issuing such patents and waiting
for them to be invalidated in adversarial proceedings such as oppositions and IPRs.
Yet surprisingly few patent offices have, to date, evidenced careful consideration of
patentability limitations on such technologies, possibly because applicants have characterized
them as products rather than medical treatments.249 Accordingly, the time is ripe for patent offices
around the world to consider the patentability of CAR-T and other gene and cell therapies in view
of national statutory and judicial limitations on the patentability of medical treatments. Such
guidance is valuable both to individual patent examiners considering complex technical
applications, as well as to the industry and patent bar.
Thus, we would recommend that the EPO move rapidly to publish definitive guidance
regarding the patentability of CAR-T and other gene and cell therapies in the Guidelines for
Examination, and that the USPTO do the same in its Manual of Patent Examination Procedures
(MPEP). With leading patent offices issuing such guidance, patent offices in other jurisdictions
will have the opportunity to consider the proper interpretation of their own laws and regulations in
this area. The lack of such guidance, however, can have a contagious effect, as patent offices that
unwittingly allow such applications in contravention of their own laws may then lead other patent
245

§ 287.
See Susan J. Marsnik, Will the America Invests Act Post-Grant Review Improve the Quality of Patents? A
Comparison with the European Patent Office Opposition, U. St. Thomas: Ethics & Bus. L. Faculty Publ’n (2012),
http://ir.stthomas.edu/ocbeblpub/25 (discussing empirical studies about what triggers opposition in the EPO and the
United States and how the opposition creates a societal benefit by reducing the number of invalid patents).
247
See What is Unified?, United Patents, www.unifiedpatents.com.
248
Sapna Kumar, Standing Against Bad Patents, 32 Berkley Tech. L.J. 87, 91, 94 (2018).
249
See EMA, Annex I: Summary of Product Characteristics, supra note 213, at 2 (specifying that Kymriah is a product
and listing it as such rather than referring to it as a medical treatment).
246
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offices considering PCT applications for the same inventions to issue patents that are contrary to
their own laws without due consideration.
C. Potential Statutory Amendments
If, as we contend, CAR-T and other gene and cell therapies are found in Europe and other
jurisdictions not to be eligible for patent protection under existing statutory and judicial limitations
on patenting medical treatments, then it is likely that a strong response from the biopharmaceutical
industry will ensue. Such responses are not without precedent and have led, among other things,
to legislative concessions including the 2000 amendments of the EPC,250 the Hatch-Waxman Act
in the United States, 251 and numerous pro-industry concessions in TRIPS and other international
trade agreements. 252 In fact, lobbying for legislative reform to counter or reverse unpopular
statutory, regulatory or judicial rules is a common tactic across industries.
As recent negotiations over intellectual property in various bilateral and multilateral trade
agreements have shown, legislatures in a number of countries have proven willing to make
concessions in order to satisfy the demands of major trading partners such as the United States. 253
Thus, it is not unlikely that some jurisdictions that currently have statutory or judicial limitations
on the ability to patent medical treatments will, in the future, consider legislation designed to limit
or overturn those limitations, at least with respect to CAR-T and other gene and cell therapies.
As these jurisdictions consider such legislation, we would urge them to recall the important
countervailing considerations promoting public health and the unfettered ability of physicians to
treat patients.
The biopharmaceutical industry is likely to oppose any formalized limitation on the ability
to patent CAR-T and other gene and cell therapies with recourse to well-known arguments
regarding the need to incentivize biomedical research and development (R&D) through patentbased exclusivity. 254 This argument, which is not wholly without merit, posits that the exclusivity
afforded by patents is necessary to enable drug and device developers to recoup their high costs of
R&D, and that without the opportunity to charge monopoly rents during this exclusive period and
block market entry by lower-priced competitors, developers would have little incentive to discover
and develop new lifesaving drugs and devices.255

250

See Sterckx & Cockbain, supra note 95, at 62–66.
21 U.S.C. § 355(j) (2017).
252
See, e.g., Ebenezer Tetteh, Pharmaceutical Innovation, Fair Following and the Constrained Value of TRIPS
Flexibilities, 14 J. World Intell. Prop. 202, 208 (2011) (“OECD nations with ethical pharmaceutical firms have taken
a pro-industry stance—and understandably so, given difficulties of balancing industrial policies, macroeconomic and
health policy objectives—to impose TRIPS-plus conditions via bilateral and region-free trade arrangements.”).
253
See United States-Mexico-Canada Agreement, Sept. 30, 2018, ch. 20, Off. U.S. Trade Representative,
https://ustr.gov/trade-agreements/free-trade-agreements/united-states-mexico-canada-agreement/agreementbetween.
254
See Sara Parker-Lue et al., The Ethics and Economics of Pharmaceutical Pricing, 55 Ann. Rev. Pharmacology &
Toxicology 191, 197 (2014).
255
Many of the assertions inherent in these arguments are contested. See, e.g., Vinay Prasad & Sham Mailankody,
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval, 177 J.
Am. Med. Ass’n Internal Med. 1569, 1569–75 (2017); Parker-Lue et al, supra note 252, at 197; Marc-Andre Gagnon
& Joel Lexchin, The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United
States, 5 PLoS Med. 29, 29 (2008), https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050001.
251
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Certainly, some ability to recoup R&D costs and avoid immediate competition from free
riders is necessary for private sector pharmaceutical developers to remain viable. However,
pricing in the pharmaceutical market today is not based on a cost-recovery model. Rather,
pharmaceutical firms appear to develop pricing strategies based on what the market will bear, or
the value that the market places on their products.256 This approach is nowhere more evident than
in the field of gene and cell therapy. As discussed in the Introduction, CAR-T treatments such as
Kymriah and Yescarta are priced at US$475,000 and US$373,000 per treatment, respectively. 257
The upward trend in pricing of gene therapies is likely to continue, as indicated by Novartis’s
recent announcement that $4-5 million per patient would be a “cost effective” price for a new gene
therapy under development for spinal muscular atrophy (SMA). 258
Yet the incremental cost of providing such treatments has been estimated by CAR-T
pioneer Carl June to be in the range of $15,000.259 Moreover, a significant portion of the R&D that
contributed to the discovery of CAR-T and other gene and cell therapies can be attributed to basic
research funded by government and philanthropic sources. For example, in the United States,
through July 2017 the National Institutes of Health have funded 365 research projects involving
chimeric antigen receptors amounting to US$204 million in financial support. 260 Of course, we
acknowledge that basic scientific research, such as that funded by the federal government, is not
sufficient to develop, test and bring a safe and efficacious therapeutic to market . Even conservative
estimates place the fully-loaded cost of developing a new cancer therapy in the neighborhood of
$650 million,261 with others estimating as high as $2.7 billion. 262 Nevertheless, there is ample
evidence that the high prices of today’s gene therapies are based not on their cost of development
or production, but on the price that the market will bear. 263

256

See Richard G. Frank & Paul B. Ginsburg, Pharmaceutical Industry Profits and Research and Development, Health
Affairs, Nov. 12, 2017.
257
See Kolata, supra note 2; Beasley, supra note 8.
258
Miller, supra note 10.
259
Final Meeting Summary of the 8th Cell Therapy/FDA Liaison Meeting, Int’l Soc’y for Cellular Therapy (2018),
https://cdn.ymaws.com/www.celltherapysociety.org/resource/resmgr/files/PDF/Meetings/CTLM/October_2008/Oct
ober_17_2008_Cell_Therapy_Liaison_Meeting_Summary_F
INAL.pdf (“Dr. June reviewed their approach to adoptive T cell therapy and clinical scale expansion which costs in
excess of $15,000 per patient.”); Donald B. Kohn et al., CARs on Track in the Clinic, 19 Molecular Therapy 432,
436 (2010) (“With respect to financial considerations, Steven Rosenberg estimated that the full costs at the NCI
Surgery Branch to produce and release an autologous gene-engineered T-cell product, including all laboratory supplies
and reagents, staff salaries, and product certification assays, amount to about $15,000 per treated patient (others
suggested somewhat higher costs per patient, in the range of $20,000 to $25,000, in part based on differing costs for
vector production and qualification). These costs do not cover capital depreciation, overhead, and rental costs;
however, the estimates compare favorably with the procurement costs for unrelated allogeneic stem cell products for
clinical transplantation.”).
260
James Love, Federal Funding to Organizations for Projects Related to Chimeric Antigen Receptors, Knowledge
Ecology Int’l (July 25, 2017), https://www.keionline.org/23838 (basing the number of projects on a study of the NIH
RePorter database as of July 2017).
261
Prasad & Mailankody, supra note 274.
262
DiMasi JA, Grabowski HG & Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D
costs, 47 J Health Econ. 20 (2016).
263
For example, Pascal Touchon, Senior Vice President of Novartis Oncology, has publicly stated that “When we
considered the price of tisagenlecleucel [Kymriah] in the United States, the first thing we looked at was its medical
value and the value it brings to patients . . . Then we looked at the value to the health-care system and society.” Jo
Cavallo, Weighing the Cost and Value of CAR T-Cell Therapy, ASCO Post (May 25, 2018),
http://www.ascopost.com/issues/may-25-2018/weighing-the-cost-and-value-of-car-t-cell-therapy/.
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At price levels such as these, lifesaving gene and cell therapies may be unaffordable to
many, including both uninsured and underinsured individuals in private insurance jurisdictions
such as the United States, and to large swaths of the population in subsidized and national
healthcare systems. Although patents are not, in themselves, the causes of exorbitant pricing for
CAR-T and other gene and cell therapies, patents enable developers to charge any price that the
relevant market will bear. Governments that face the decision of whether to allow patents on gene
therapies or not should always put monopolies, rather than patients, at risk. Giving the fact that the
business model of private sector pharmaceutical developers relies, at least in part, on obtaining
these patents, we recognize that fully exercising this patentability exclusion could lead to a broader
debate on how to induce private investments in these new therapies. While that debate falls outside
the scope of this paper, we believe that the discussion should be based on alternative mechanisms
for inducing innovation, such as progressive delinkage, and not about eliminating limitations on
patentable subject matter to include gene therapies.264
CONCLUSIONS
More than eighty countries, including the members of the European Patent Convention, the
United States, Canada, New Zealand, China, Japan, and India, currently exclude or limit the
patentability of methods of medical treatment. CAR-T and other recent gene and cell therapies,
which operate based on the extraction of genetic or cellular material from a patient, the alteration
of such material, and the reintroduction of such material to the patient’s body, have been
characterized by their developers as products. Yet this characterization is largely a fiction. These
therapies are more akin to medical treatments such dialysis than manufactured products and should
thus, under most or all of these legal regimes, be excluded from patentability, or be subject to
limited patent enforcement. Accordingly, we urge national patent offices to update their
examination procedures and practices to take these patentability limitations into account and to
publish guidance clearly explaining this approach to applicants.

Delinkage “describes the idea that temporary monopolies and the associated high drug prices should not be used
to fund pharmaceutical research and development, as well as a set of policy proposals that would replace monopolies
and high prices with alternative incentives based upon cash rewards, and expanded funding for research, drug
development, and clinical trials through a combination of grants, contracts, tax credits, and other subsidies.”
Progressive de-linkage means that governments implement reforms over time that sequentially and progressively
move prices closer and closer to affordable generic prices, and reform incentives so they no longer rely upon high
prices. See What is Delinkage?, Delinkage.org (Feb. 28, 2016), https://delinkage.org/overview/.
264
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APPENDIX A
International Trade Agreements Including Exclusion of Medical Treatment Patents
Canada – Korea (article 16.12)
China – Korea (article 15.15)
Colombia – EFTA (article 6.9)
EU – CARIFORUM (article 148)
Japan – Switzerland (article 117)
Korea – Australia (article 13.8)
Korea – Vietnam (article 12.7)
NAFTA 1992 (article 1709)
Peru – EFTA (article 6.9)
Switzerland – China (article 11.8)
USA – Australia (article 17.9)
USA – Bahrain (article 14.8)
USA – Jordan (article 4.18)
USA – Oman (article 15.8)
US–DR–CAFTA (article 15.9)
US – Colombia (article 16.9)
US – Peru (article 16.9)
TPP/CPTPP (article 18.37)
USMCA (article 20.36.3(b))
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APPENDIX B
Countries Implementing Exclusion for Medical Treatment Patents in National Legislation
Argentina: Article 6(e) of Law 24.481 enacted on March 1995
Albania: Article 6.4 of Law No. 9947 enacted on July 7, 2008 as amended up to Law No.
55/2014 of May 29, 2014
Andean Community: Article 20(d) of Decision No. 486 Establishing the Common
Industrial Property Regime, adopted on September 13, 2000
Bahrain: Article 3(d) of Law No. 1 of 2004 on Patents and Utility Models, enacted up to
January 23, 2004
Barbados: Article 11(c) of the Patents Act 2001, enacted July 25, 2001 as amended by Act
No. 2 of 2006
Belgium: Section 7.2 of the Patent Law of March 28, 1984, as amended up to December
22, 2008
Brunei Darussalam: Section 16 of the new Patents Act (2011)
China: Article 25 of the Patent Law
Chile: Article 37(d) of Law No. 19.039 on Industrial Property, consolidated text as of
February 6, 2012
Costa Rica: Article 1.4(b) of Law 6867 enacted on April 1983 and last amended on
November 2008
Croatia: Article 6.3 of the Patent Act, enacted on October 14, 2003
Ecuador: Article 273.2 of the Organic Code on the Social Economy of Knowledge,
Creativity and Innovation, enacted on November 30, 2016
Egypt: Article 2.3 of the Law No. 82 of 2002 on the Protection of Intellectual Property
Rights, enacted on June 1, 2002
El Salvador: Article 107(c) Law on Intellectual Property enacted on July 14, 1993, as
amended up to Legislative Decree No. 611 of February 15, 2017
Estonia: Section 7.2 of the Patents Act enacted on March 15, 1994, consolidated text of
January 1, 2015
European Union: Article 53(c) of the European Patent Convention (16th edition) published
on June 2016
France: Article L611-16 of the Intellectual Property Code enacted on June 30, 1992,
consolidated version of March 17, 2017
Georgia: Article 17(b) of the Law No. 1791 enacted on February 5, 1999, as amended up
to Law No. 3031 of May 4, 2010
Germany: Section 2(a)1 of the Patent Act, as amended up to Act of October 8, 2017
Ghana: Section 2(c) of the Patent Act 2003 enacted on December 30, 2003
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Guatemala: Article 92(a) of the Industrial Property Law enacted on September 17, 2000
Honduras: Article 5.9 of the Industrial Property Law enacted on December 29, 1999
Iceland: Article 1 of the Patents Act No. 17/1991, as amended up to Act No. 126/2011
India: Article 3(i) of the Patents Act enacted on September 1970 and as amended up to
April 2005
Indonesia: Article 7 of the Law of the Republic of Indonesia No. 13 on Patents enacted on
July 28, 2016
Israel: Article 7 of the Patent Law, 5727-1967, consolidated version of 2014
Jordan: Article 4(c) of the Law No. 32 of 1999 on Patents, enacted on September 19, 1999
Kenya: Article 21.3(c) of the Industrial Property Act 2001 (Act No. 3 of 2001), as amended
up to Act No. 11 of 2017
Lebanon: Article 3.3 of the Law No. 240/2000 of 2000 on Patents, enacted on August 6,
2000
Lithuania: Article 2 of the Law No. I-372 of January 18, 1994, on Patents, as amended by
Law No. X-1119 of May 10, 2007
Malaysia: Article 13(d) of the Patents Act 1983, enacted on 1983 as amended up to August
2006
Malta: Article 4.4 of the Patents and Designs Act (Chapter 417), enacted on May 31, 2002
Mauritius: Article 11.3(c) of the Patents, Industrial Designs and Trademarks Act 2002
enacted on July 1, 2002
Mexico: Article Art. 19.VII of the Industrial Property law enacted on June 1991,
consolidated text published in the Official Journal of the Federation on March 13, 2018
Montenegro: Article 7.2 of the Law on Patents enacted on July 15, 2015
Morocco: Article 24(b) of Law No. 17-97 on the Protection of Industrial Property enacted
on February 14, 2000, as amended by Laws No. 31-05 and No. 23
New Zealand: Article 16.2 of the Patents Act 2013 enacted on September 12, 2013
Nicaragua: Article 7(b) of Law on Patents, Utility Models and Industrial Designs (No. 354
of 2000) enacted on May 31, 2000
Norway: Section 1 of the Patents Act No. 9 enacted on December 15, 1967, consolidated
text of 2018
Panama: Article 14.7 of Law No. 35 enacted on May 10, 1996, on Industrial Property
Papua New Guinea: Section 2 of the Patents and Industrial Designs Act 2000 enacted on
June 30, 2000
Paraguay: Article 4(e) of Law No. 1.630/2000 on Patents, as last amended by Law No.
2.593/2005
Philippines: Section 22.3 of the Intellectual Property Code of the Philippines (Republic Act
No. 8293)
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Poland: Article 29(iii) of the Industrial Property Act of June 30, 2000, as amended up to
Act of July 24, 2015
Portugal: Article 53.3(c) of the Industrial Property Code, as amended up to Law No.
46/2011 of June 24, 2011
Romania: Article 8(d) of Law No. 64/1991 on Patents (as amended up to Law No. 83/2014)
Serbia: Article 9.2 of the Law on Patents No. 99/2011, enacted on December 25, 2011
Singapore: Section 16(2) of the Patents Act (No. 24 of 2001), as amended by Act No. 2 of
2007
Slovakia: Article 6.1(c) of the Act No. 435/2001 Coll., consolidated version of 2009
Spain: Article 5.4 of the Law No. 24/2015 of July 24, 2015, on Patents
Sweden: Article 1 of the Act (2004:159) Amending the Patents Act (1967:837)
Switzerland: Article 2 of the Federal Act of June 25, 1954, on Patents for Inventions, as
amended up to January 1, 2017
Thailand: Article 9.4 of the Patent Act B.E. 2522 (1979), as amended up to December 31,
1998
FYR Macedonia: Article 26 of the Law on Industrial Property enacted on January 11, 2009
Seychelles: 6.1(e) of the Industrial Property Act 2014 enacted on April 15, 2014
Trinidad and Tobago: Article 12.1(d) of the Patents Act, 1996 enacted on December 31,
1995
Tunisia: Article 2(d) of the Law No. 2000-84 of August 24, 2000, on Patents
United Kingdom: Article 4A of the Patents Act 1977, as amended by the Patents Act 2004
Uganda: Article 8.3(c) of the Industrial Property Act, 2014, enacted on January 5, 2014
Uruguay: Article 14(a) of Law No. 17.164 of September 2, 1999, regulating Rights and
Obligations relating to Patents, Utility Models and Industrial Designs
Vietnam: Article 59.7 of the Law No. 50/2005/QH11 enacted on November 29, 2005, on
Intellectual Property
Zambia: Article 17(a) of the Patents Act 2016

Electronic copy available at: https://ssrn.com/abstract=3391788

